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Embryonic Development 
Almost all forms of life, as most of us are familiar with, are the result of a close collaboration between billions 
of cells. Together, these cells form the animal body plan with numerous highly specialized organs and 
tissues. This beautiful and at the same time extremely complex cooperative multicellular entity has been 
build up from an 1-cell embryo that was born upon the fusion of an oocyte and sperm cell. The subsequent 
development of a multicellular organism comprehends two tightly coordinated processes that run in parallel: 
the steady increase in cell numbers through serial cell divisions and the tightly controlled cell specification 
through (epi)genetic regulation of gene expression. During cell division cells copy their genetic material and 
divide into two genetically identical daughters cells, a process that is already repeated roughly 40 times 
during human embryonic development prior to birth. Upon fertilization the oocyte starts to proliferate and at 
the morula stage, when the embryo consists of 16-32 cells, these cells from a ball-like structure. 
Characteristic to this initial phase of embryonic development is the rapid expansion of cell numbers while 
the volume of the embryo remains constant, resulting in compaction of the cells. Albeit all these cells contain 
the exact same genetic material, the fate of these cells branches for the first time: the outer trophoblast 
cells will develop into the extra-embryonic tissue whereas the inner embryoblast cells will eventually form 
the embryo and yolksac. Because the trophoblast cells produce a fluid that is stored within the ball-like 
structure, a cavity is formed, the blastocoel. Within the so-called blastocyst the embryoblasts clump together 
on one side of the embryo, forming a group of cells that is called the Inner Cell Mass (ICM). At this stage 
ICM cells from the early blastocyst will undergo global epigenetic reprogramming that results in global 
erasure of maternally and paternally inherited epigenetic marks (reviewed by Wu, H. & Zhang1). At the 
same time Fibroblast Growth Factor (FGF)/Extracellular signal-Regulated Kinase (ERK) signaling in the 
ICM drives differential expression of the key Transcription Factors (TFs) NANOG and GATA6 that will 
instruct the establishment of the epiblast, that will form the embryo, and the extra-embryonic hypoblast, 
respectively (reviewed by Frum, T. & Ralston2). Around time of implantation of the blastocyst in the uterine 
wall another cavity (the amniotic cavity) forms and the epiblast reorganizes in a cup-shaped structure, the 
egg cylinder. This structure is composed of a double cell layer of primed epiblast and primitive endoderm 
cells. The epiblast cells will form the ectoderm whereas the mesoderm and definitive endoderm will 
subsequently be formed through invagination and migration of ectodermal cells, processes tightly controlled 
by TGF-β and Wnt signaling (reviewed by Beddington, R. S. P. & Robertson, E. J.3). These three germ 
layers will eventually give rise to all cell types of the animal body plan.  
Embryonic Stem Cells; what’s the fuss about? 
Prior to germ layer specification cells from the blastocyst reside for a limited period of time in an 
undifferentiated state and are called Embryonic Stem Cells (ESCs). The establishment of in vitro culture 
conditions that allowed scientist to capture these cells in their undifferentiated state in the early 80s of the 
last century opened new exciting possibilities for research4. Similar to their in vivo counterparts, in vitro 
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cultured ESCs are pluripotent, meaning that they have the potential to differentiate in any kind of cell type 
of the fully developed body plan. The ultimate proof that these in vitro propagated ESCs are truly pluripotent 
comes from the fact that they will continue to contribute to embryonic development and the eventual body 
plan upon injection in the ICM. An ESC-specific TF network regulates the expression of genes important 
for the maintenance of pluripotency and the repression of lineage specifying genes. At the core of this 
network act the TFs OCT4, NANOG and SOX2, which have overlapping genomic binding sites and 
coordinately ensure maintenance of pluripotency5. Intensive research on the signaling pathways that 
mediate cell fate specification has resulted in a wide range of protocols that provide efficient differentiation 
of pluripotent stem cells into cells from all three lineages (reviewed by Bartfeld, S. & Clevers, H.6). 
Another characteristic of ESCs is there unrestrictive proliferative capacity which facilitates the cultivation of 
large numbers of cells. Although new methods are being developed to study molecular processes on single 
cell level, large cell quantities facilitate a variety of biochemical analysis to decipher molecular processes 
involved in development and disease, like gene expression and transcription factor binding. Moreover, the 
virtually unlimited number of ESCs that can be obtained is crucial in regenerative medicine, where the 
ultimate goal is to use stem cells to replace or support lost or damaged tissues7. Using well-defined 
differentiation conditions in combination with 3D culture platforms scientist have been able to grow 
numerous fully differentiated mini-organs from stem cells (reviewed by Bartfeld, S. & Clevers, H.6). These 
so-called organoids might not only serve to replace lost tissue but also allow scientists to study the role of 
genes in developmental and disease. In this regard recent advances in genome wide targeted gene editing 
techniques offer new exciting possibilities to study genes and regulatory elements in development and 
disease in an unbiased approach8–10. 
The above-mentioned properties and potential clinical applications have driven scientist to unravel both the 
molecular mechanisms employed by ESCs to remain pluripotency as well as the pathways that regulate 
ESC proliferation. Interestingly, research over the past decades has shown that members of the cell cycle 
regulatory network can regulate the pluripotency network and vice versa (reviewed by Kareta, M. S., Sage, 
J. & Wernig, M.11). One of the main goals of this thesis is to comprehensively describe how the ESC cell 
cycle is regulated. To this end a basic understanding of the mammalian cell cycle is crucial and I will therefor 
first elaborate on this subject. 
The Cell Cycle; the Basics 
In proliferating cells the mitotic phase, during which the cell divides, alternates with an interphase. During 
interphase cells grow, replicate their DNA and prepare for mitosis. The interphase can be subdivided in 
three phases, gap-phase 1 (G1), the DNA synthesis-phase (S) and gap-phase 2 (G2). In the currently 
prevailing view progression through the cell cycle is driven by protein complexes that consist of a cyclin and 
a Cyclin Dependent Kinase (CDK). The cyclins, as their name already implies, are a family of proteins first 
discovered in sea urchins that undergo cyclic expression during the course of a cell cycle12. The cyclins are 
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highly conserved throughout the animal kingdom and at present over 25 mammalian proteins containing a 
‘cyclin box’ have been identified with a wide range of functions13. The primary function of the best studied 
cyclins is however considered to be the activation of CDKs. Pioneering studies in yeast and frogs identified 
CDKs as mediators of cell cycle progression, but work over the past three decades has identified CDKs 
and CDK-like proteins that function in either cell cycle progression or in transcriptional regulation (reviewed 
by Malumbres, M.14). Although the current model designates the activity of different CDK/Cyclin complexes 
to different phases of the cell cycle it has to be mentioned that there is a significant degree of plasticity in 
both the role of cyclins as well as CDKs. CDK1 can for example interact with CYCLIN D and CYCLIN E, 
can functionally replace CDK2-4 and is the only CDK essential for the first cell divisions after fertilization15. 
Similarly, the combined deletion of all Cyclin D and Cyclin E isoforms does not necessarily stop the cell 
cycle16. 
In their active configuration the pocket proteins RB, P107 and P130 bind and inhibit chromatin-bound E2F 
TFs. Waves of cell cycle phase-specific cyclins bind to and activate CDKs that in turn activate E2F-mediated 
transcription through phosphorylation and inactivation of the pocket proteins17. To date, nine structurally 
related proteins have been classified as the E2F protein family. In general these members are considered 
to either mediate transcriptional activation (E2F1, E2F2, E2F3a & E2F3b) or repression (E2F4, E2F5, E2F6, 
E2F7 & E2F8) although switching between both functions has been observed indicating that this model is 
simplified18. The E2F transcription factors drive the expression of a suite of proteins needed for the next 
phase of the cell cycle.  
G1-phase 
Cells in G1-phase grow and produce proteins necessary for DNA replication. Progression through the G1-
phase is dependent on extracellular mitogens that stimulate the ERK signaling pathway. Upon stimulation 
of FGF membrane receptors consecutive phosphorylation steps culminate in the activation of transcription 
factors, amongst others MYC, that regulate the expression of cell cycle mediators like CYCLIN D19. In the 
widely accepted model an initial burst of CYCLIN D/CDK4-6 activity results in phosphorylation and 
inactivation of the pocket proteins, RB, P107 and P130, thereby alleviating repression of the E2F 
transcription factors20. Consequently, E2F activity results in the expression of Cyclin E and Cdc25a, a 
phosphatase that removes inhibitory phosphate groups from CDK2. Subsequently, CDK2 partners with 
Cyclin E into a complex that further increases the phosphorylation of the pocket proteins, thereby 
participating in a feed forward loop that ensures progression into S-phase21. It is assumed that this feed 
forward loop results in a bimodal E2F transcription factor activity19,22 and marks a specific point during G1-
phase at which is switched to either quiescence or growth, the so-called “Restriction point”23. If extrinsic 
mitogenic stimuli result in sufficient CYCLIN D/CDK4-6 activity to induce Cyclin E/CDK2 activity, cells cross 
this point and will complete a full cell cycle, irrespective of the availability of extracellular stimuli. Interestingly 
though, malignant cells as well as certain primary cells lines do not have a restriction point and proceed to 
S-phase in the absence of serum stimulation19,21,23. 
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Alternative to progressing through G1-phase, cells can also (ir)reversibly enter a non-proliferative quiescent 
state. Cellular quiescence can protect cells from stress and toxicity and is of particular importance for long 
lived cells like adult stem cells and terminally differentiated cells24. In case of lack of nutrients or in case of 
DNA damage, several pathways are able to halt G1-progression to prevent these cells from entering S-
phase in order to maintain genomic integrity. P53 plays a key role in halting G1-phase progression. After 
its discovery in the late 70s / early 80s of the last century it became clear that P53 is an important tumor 
suppressor gene and mutated in a wide range of tumours25–27. Upon DNA damage or stress P53 controls 
several responses that can lead to either apoptosis or cell cycle quiescence28,29. P53 can prevent cell cycle 
commitment either by counteracting the expression of cyclins30 or by regulating the expression of several 
Cyclin-Dependent Kinase inhibitor’s (CDKi’s). The latter interfere with CDK/cyclin complex formation and 
thereby abrogate G1-phase progression. P53 is a direct transcriptional activator of Cdkn1A, the first 
mammalian CDKi described that codes for the protein P21. The P53-P21 axis is now being recognized as 
a major pathway in cell cycle control. P21 together with P27 and P57 belong to the Cip and Kip family of 
proteins that prohibit cell cycle progression through a multitude of mechanisms. Although these proteins 
are able to directly regulate gene transcription they are best known for their ability to prohibit RB 
phosphorylation by competing with CDK1-2/CYCLIN E complex formation. This process will delay S-phase 
entry and allow DNA damage repair (reviewed by Abbas, T. & Dutta, A.31). 
S-phase 
Once the quality of DNA is ensured and the cells have passed the restriction point and committed to another 
cell cycle, the DNA is replicated during Synthesis (S) phase. Replication of the DNA starts at particular DNA 
sequences, so called origins of replication (Ori’s), from where replication forks move in both directions. The 
sequence with which these Ori’s fire is tightly regulated (known as the replication timing program) and highly 
specific for each cell type32. Faithful replication of the DNA can be compromised by various endogenous 
and exogenous conditions33. In concordance with the G1 checkpoint, several surveillance pathways are 
active during S-phase to either recognize flawed DNA replication or signal when DNA replication forks 
stall34. 
G2-phase 
Prior to cell division the cell increases in size and synthesize proteins needed for division during G2-phase. 
Progression through this phase is mediated by CYCLIN B/CDK1 complexes and involves a positive 
feedback mechanism driven by the CDC25 proteins (reviewed by Schmidt, M. et al.35). Interestingly, recent 
studies have indicated that decisions on G1-phase progression are already made during G2-phase of the 
preceding cell cycle. Both mediators of mitogenic signaling as well as stress response pathways in the 
mother cell are transmitted upon mitosis influencing progression through G1 phase of the newborn daughter 
cells36. ERK signaling during G2 phase results in elevated levels of cyclin E RNA which are transferred 
during mitosis and abolish the restriction point in the newborn daughter cells37. Another very recent study 
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indicates that not only Cyclin D RNA but also DNA damage-induced P53 protein is transferred from mother 
to daughter cells and influence G1-progression. Activated P53 results in higher levels of Cdkn1a RNA in 
the daughter cells which upon translation counteracts CYCLIN D/CDK2 activity30. 
Back to the Embryonic Stem Cell and its cell cycle  
During early embryonic development cell proliferation and migration are tightly controlled. Cells in the ICM 
of the early blastocyst proliferate at a rapid pace with doubling times of around 8 to 10 hours. During the 
peri-implantation stage these cells start to proliferate even faster, resulting in a doubling time as short as 
roughly 4 hours. Early studies using ESCs as in vitro counterparts of ICM cells revealed that these cell 
cycle characteristics can be attributed to the precocious expression of CDKs, in particular CDK2, and their 
catalytically active subunits (the cyclins), resulting in an absence of hypo-phosphorylated RB protein38,39. 
Furthermore, ESCs lack the expression of the CDKi’s and, if expression of the CDK-inhibitor P16 is forced, 
seem insensitive to CDKi activity. This could also explain why proliferation of ESCs is unaffected neither by 
serum starvation nor by contact inhibition. As a result of this characteristic cell cycle regulatory network, 
mouse ESCs reside only for a short period of time in G1 phase, which is reflected by a high number of cells 
in S-phase when compared to somatic cells39. Because several studies have indicated that differentiation 
is initiated during G1 phase, reflected by changes in the epigenetic landscape and expression of 
developmental genes, it has been postulated that the characteristic short G1-phase protects ESCs from 
differentiating40–42. On the other hand, however, it was shown that artificial elongation of G1-phase did not 
affect pluripotency43 and certain signaling pathways not only ensure maintenance of pluripotency but 
elongate the G1-phase as well44,45. Additionally, a recent study revealed that P53-driven enhancement of 
TGF-β signaling blocks pluripotent state dissolution specifically during S and G2 phase, which forms an 
alternative explanation for the fact that ESCs are more prone to differentiate during G1 phase46. So, it is 
still not entirely clear to what extend the short G1-phase contributes to the pluripotency network in ESCs or 
is merely a consequence of the ESC-specific transcriptional program. 
Serum and 2i ESCs 
Although the isolation and propagation of ESCs on growth-arrested Mouse Embryonic Fibroblasts (MEFs) 
was first described almost 50 years ago the elucidation of the exact pathways that ensure maintenance of 
pluripotency and allow in vitro culturing of ESCs is still ongoing. Seminal research in the late 80s led to the 
discovery that the addition of LIF potently inhibits ESC differentiation and could replace MEFs, allowing 
long-term propagation of naive ESCs in the absence of feeders47,48. However, the in vitro expansion of 
pluripotent ESCs remained dependent on the addition of serum components. Disadvantages of the serum 
include batch-to-batch variation that causes variation in cell culture conditions. Moreover, the addition of 
this black-box containing a mixture of unknown growth factors and signaling molecules could potentially 
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hamper the identification of true ESC characteristics. Research over the last couple of decades resulted in 
the identification of several key signaling pathways involved in stem cell maintenance and 
differentiation49,50. Using this knowledge, a method to propagate ESCs in vitro without the need for either 
MEFs or serum was developed in 2008. This new culture system allows maintenance of pluripotent ESCs 
in vitro solely by shielding them from differentiation-inducing cues proving that “extrinsic stimuli are 
dispensable for the derivation, propagation and pluripotency of ES cells”51. The inhibition of FGF/ERK 
signaling by PD0325901 (hereafter referred to as “PD”) protects ESCs from auto-inductive FGF whereas 
CHIR9021 (“Chiron”) inhibits GSK3-α and –β and restores biosynthetic pathways essential for self-renewal. 
In addition, Chiron prevents neural differentiation presumably through the activation of TGF-β signaling and 
relieving repression of amongst others Esrrb and Nanog51,52. Several lines of research have been set out 
to compare ESCs cultured in conditions containing either serum or the two small molecule inhibitors 
(referred to as “naive serum ESCs” and “ground state 2i ESCs”, respectively) and revealed some 
remarkable differences. Although genes of the core pluripotency network are expressed to a similar level, 
some factors that contribute to maintenance of pluripotency in naive serum ESCs, e.g. MYC and the ID 
proteins, are lower expressed in 2i ESCs. The expression of lineage specifiers is however higher in serum 
ESCs and might be hold accountable for the fact that serum ESCs are more heterogeneous than 2i ESCs 
in terms of morphology53,54. Along with data on the epigenetic landscape of both ESC populations that 
indicate a higher number of bivalent domains which are known to concur with developmental genes 
suggesting that serum ESCs are primed for differentiation. Assessment of genome-wide DNA methylation, 
an epigenetic modification that correlates with differentiation, revealed that ground state 2i ESCs have low 
DNA methylation levels that resemble the pre-implantation ICM whereas naive serum ESCs have elevated 
levels of DNA methylation55–57. Together these results have led scientists to believe that naive serum and 
ground state 2i ESCs reflect pluripotent cells from pre- and post-implantation stages, respectively54. Another 
striking difference between serum and 2i ESCs is the expression of proteins of the cell cycle machinery53. 
In general, cyclin-dependent kinases are higher expressed in serum ESCs and the CDK-inhibitors P16, 
P19 and P21 are exclusively present in 2i ESCs. The studies described in this thesis will shed light on how 
these differences affect the ESC cell cycle and relate to developmental stages in vivo. 
The Cell  Cycle and Colorectal Cancer 
Not only during development but also in cells of the fully developed body, a tightly regulated cell cycle is of 
utmost importance. In most tissues a population of adult stem cells exists that is needed for tissue 
homeostasis and replenishment of lost cells. Although these cells in general reside in a non-proliferative 
quiescent state they can be stimulated to produce cells that differentiate and repopulate the organ24. 
Dysregulated expression of genes involved in cell cycle progression often cause uncontrolled proliferation. 
Uncontrolled proliferation is one of the hallmarks of cancer and mutations that contribute to cancer 
development are often found in genes that regulate progression through G1-phase58. Although mutations 
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in these coding regions often result in mis-expression of the affected gene, Genome-Wide Association 
Studies (GWAS) have revealed that mutations linked to an increased risk of cancer are often located in 
genomic regions that are not transcribed. Possibly, these non-coding regions regulate the expression of 
genes located down- or up-stream. Although a great number of Single Nucleotide Polymorphisms (SNPs) 
in regulatory regions associated with cancer predisposition has been identified, it is often unknown how 
they affect gene expression. Presumably, SNPs in non-coding regions affect the binding of TFs thereby 
affecting the expression of nearby genes. 
Outline of this thesis 
Considering the role of the CDK/Cyclin pathway in G1-phase progression recently observed differences 
between serum and 2i ESCs imply that the cell cycle of the latter is different from that of the serum ESC-
specific short G1-phase. In chapter 1 we describe how the differential expression of cyclins and CDKs 
impact on the cell cycle of 2i ESCs. We will also elucidate on the signaling pathways that drive these 
differences. 
Although DNA damage pathways are abrogated in mouse ESCs, some of the results we describe in chapter 
2 imply that the role of P53 in 2i ESCs is different from that in serum ESCs. In chapter 2 we set out to 
investigate the role of the P53 pathway in 2i ESCs. 
In chapter 3 we will briefly review how the cell cycle of mouse serum ESCs is different from 2i ESCs. We 
will consider how the pluripotency network contributes to the abbreviated G1-phase. In addition, we will 
discuss how members of the G1-phase control pathway directly interact with the core pluripotency network.  
Many SNPs have been identified within non-coding regions that increase the risk of an individual to develop 
Colorectal Cancer (CRC). In chapter 4 we set out to investigate how these mutations affect Transcription 
Factor (TF) binding. To assess the effect of SNPs in CRC risk loci we performed a Proteome-Wide Analysis 
of SNPs (PWAS). Using this quantitative mass spectrometry approach on a library of 116 susceptibility loci 
we identified several candidate TFs that showed favored binding in either the WT locus or in the one 
harboring the SNP. In addition, we describe several follow up experiments that unravel a potential 
mechanism by which SNP increases the risk on CRC development. 
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Summary 
Mouse embryonic stem cells (ESCs) cultured in serum are characterized by hyper-phosphorylated 
RB protein, lack of G1 control and rapid progression through the cell cycle. Here, we show that 
ESCs grown in the presence of two small molecule inhibitors (2i ESCs) have a longer G1-phase with 
hypo-phosphorylated RB, implying that they have a functional G1 checkpoint. Deletion of RB, p107 
and p130 in 2i ESCs results in a G1-phase similar to that of serum ESCs. Inhibition of the ERK 
signaling pathway in serum ESC results in the appearance of hypo-phosphorylated RB and 
reinstatement of a G1 checkpoint. In addition, induction of a dormant state by the inhibition of MYC, 
resembling diapause, requires the presence of the RB family proteins. Collectively, our data show 
that RB-dependent G1 restriction point signaling is active in mouse ESCs grown in 2i but abrogated 
in serum by ERK-dependent phosphorylation. 
Main Text 
One characteristic of ESCs is that they proliferate at an unusually rapid pace, with a doubling time of ~12-
14hr. The highly proliferative nature of pluripotent ESCs is attributed to the lack of G1-phase control, a 
feature that has been intimately linked to pluripotency1. Constitutively active kinases and the absence of 
CDK-inhibitor proteins ensure rapid progression into S-phase, resulting in an extremely short G1-phase. 
This model is, however, based on studies performed in ESCs grown in serum (hereafter serum ESCs). 
Recent studies have indicated that ESCs cultured in defined medium in the presence of two small molecule 
inhibitors, PD0325901 and CHIR99021, (hereafter 2i ESCs) more closely reflect pluripotent ESCs from the 
inner cell mass (often referred to as ground state) whereas ESCs cultured in serum are more similar to 
pluripotent cells from post-implantation embryonic stages2–4. Our analysis of the cell cycle in 2i ESCs 
indicates that G1 control in ground state pluripotent ESCs is distinct from that in serum ESCs. 
To assess the global effect of the 2i culture conditions on the mouse ESC cell cycle, we used BrdU 
incorporation and Propidium Iodide (PI) staining in combination with flow cytometry to determine the 
distribution of cells over the different phases of the cell cycle. In line with literature, the majority of serum 
ESCs reside in the S-phase whereas the rest are roughly equally distributed between G1 and G2 phase 
(Figure 1A). Conversely, the number of 2i ESCs in S-phase is reduced whereas the number of cells in the 
G1-phase is strongly increased which is largely effectuated already within 24 hours of adaptation from 
serum-to-2i or vice versa (Figure 1B and S1A). The adaptation of serum ESCs to 2i conditions does not 
affect the expression of key pluripotency factors3, indicating that these changes in cell cycle are not the 
result of differentiation (Figure S1B). Similar results were obtained in multiple karyotyped WT ESC lines, 
both male and female with several different genetic backgrounds and in iPS cells5 (Table S1, Figure S1C 
and Figure S1D). 
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Serum grown ESCs have been reported to contain Nanog-high and Nanog–low subpopulations with the 
former exhibiting a higher degree of pluripotency6,7. Both populations display a serum-type cell cycle 
distribution (Figure S1E), indicating that the elongated G1-phase is characteristic of ground state 2i ESCs. 
To gain further insight, we generated mESCs expressing the FUCCI reporters8. The FUCCI system enables 
FACS sorting of cells from different phases of the cell cycle and importantly determination of the length of 
the different phases, because the reporter activity increases proportionally to the time spent in a specific 
phase (Figure S1F). The analysis confirms that 2i ESCs have a markedly longer G1-phase and shorter S-
/G2-phases, relative to serum ESCs (Figure 1C and S1G). As serum and 2i ESCs proliferate at roughly 
similar pace (Figure S1H)9 these changes appear to have a compensatory effect on the length of the cell 
cycle. 
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The abbreviated G1-phase in serum ESCs is accompanied by the accelerated expression of histones 
during G1-/S-phase transition10. To assess whether serum and 2i ESCs differ in this respect, we performed 
RNA-seq on 2i and serum ESCs in G1-phase. GO-term analysis on differentially expressed genes (Figure 
S1I; Fold Change >2, p-val<0.05) revealed higher expression of genes associated with S-phase entry and 
chromatin assembly in serum ESCs (Figure S1J). Replication-dependent histone genes are more highly 
expressed in serum ESCs when compared to 2i ESCs both in late G1 as well as in early G1-phase (Figure 
S1K and not shown). The accelerated progression through G1-phase, upregulation of histone gene 
expression, enrichment of the E2F binding motif at highly expressed genes (Figure S1L) as well as 
increased expression of the E2F family members and known E2F target genes (Figure S1M) suggest 
elevated activity of the RB-E2F pathway in serum ESCs. E2F1 ChIP-seq revealed that ~5% of the binding 
sites displayed differential binding (2-fold change, p-val<0.05) between serum and 2i  (Figure S1N). 
However, E2F1 occupancy did not correlate with differential RNA expression (R2 = 0.08). Thus differential 
E2F binding is very unlikely to drive differential gene expression in serum and 2i. 
To assess whether cyclin/CDK activity upstream of the RB-E2F pathway explains the distinct cell cycle 
patterns, we determined the expression of key regulators of cell cycle progression through G1-phase. 
Quantitation of their protein levels throughout the cell cycle revealed that CDK2 and CDK4 are slightly 
lower, whereas CDK6, CCND and CCNE are slightly higher expressed in 2i ESCs (Figure 1D). The most 
notable difference, however, is the higher protein levels of the CDK-inhibitors: P16, P21 and P27 are nearly 
exclusively expressed only in 2i ESCs and primarily during the late G1-phase (Figure 1D). Importantly, 
differential expression of CDK-inhibitors in 2i and serum ESCs parallels their higher RNA levels in Inner 
Cell Mass as compared to the Epiblast11 (Figure S2A).  
Figure 1. G1-phase is elongated upon adaptation of ESCs to 2i conditions. (A) DNA staining using 
PI in combination with BrdU incorporation shows a higher number of 2i R1 ESCs residing in G1 phase 
when compared to serum R1 ESCs. Significance was tested using the two tailed Student’s T-test; *p-
val<0.05. (B) Cell cycle analysis using BrdU/PI shows that the rapid increase in the number of cells 
residing in G1-phase upon transition from serum to 2i occurs within 48 hours. Similar results were 
observed in several different male and female ESC lines. (C) FUCCI reporter expression shows that 2i 
ESCs reside longer in G1 phase, whereas the combined S-/G2-phase is shortened in 2i ESCs 
compared to serum ESCs. Indicated are the gates as used for sorting. (D) Western Blot analysis of cell 
cycle proteins involved in progression into S-phase in serum and 2i ESCs showing specific upregulation 
of the CDK-inhibitors in 2i ESCs during both Early as well as Late G1-phase (EG1 and LG1, 
respectively). Three independent experiments showed similar results. (E) Distribution of cells over 
different phases of the cell cycle as determined by BrdU/PI staining performed in triplicate using three 
independent P21/P27 DKO clones. A two tailed Student’s T-test was used to determine significance; 
*p-val<0.05. (F) Western blot analysis of total cell populations showing only phosphorylated RB in serum 
ESCs. Western blot is representative for three independent experiments. (G) As in C, using sorted Early 
and Late G1 as well as S-/G2-phase of ESCs, showing hypo-phosphorylated RB in G1-phase and 
phopho-RB in S-/G2 in 2i ESCs. At least two independent experiments showed similar results. (H) Cell 
cycle analysis on RB/P107/P130 TKO ESCs using BrdU in combination with PI showing unaltered 
number of cells in G1-phase upon adaptation from serum to 2i. A decrease in the number of cells in G2-
phase was observed. Results are representative of at least two independent experiments (*p-val<0.05, 
two tailed Student’s T-test). See also Table S1 and Figure S1 and S2. All values and error bars 
represent the mean ± SD. 
Distinct cell cycle control in two different states of mouse pluripotency 
23 
1 
Deletion of P21 or P27 alone did not significantly alter the cell cycle, however, the combined deletion of 
P21 and P27 resulted in a decrease in the number of cells in G1-phase as well as lowered expression of 
the FUCCI reporters. The deletion of P16, alone or in combination with P21, did not significantly affect the 
number of cells in G1-phase (data not shown). These results indicate that the CDK-inhibitor proteins have 
partially overlapping functions and that the length of G1-phase in 2i ESCs is controlled by the sum of 
P21/P27 inhibitory action (Figure 1E, S2B, S2C and S2D). 
To assess the net effect of differential CDK-activity between serum and 2i ESCs, we determined the 
expression and phosphorylation status of their downstream targets, the RB family proteins RB, P107 and 
P130. In the hypo-phosphorylated form, these proteins bind to and inhibit the activity of DNA-bound E2F 
transcription factors, thereby slowing down cell cycle progression during G1-phase. Upon successive 
phosphorylation of RB, its interaction with E2F transcription factors is lost leading to the activation of genes 
involved in progression into S-phase12,13. Western blot analysis shows that hyper-phosphorylated forms of 
RB are detected in serum ESCs whereas RB appears hyper- as well as hypo-phosphorylated in 2i FUCCI 
ESCs, which was confirmed by phosphatase treatment (Figure 1F and S2E). Strikingly, in both early and 
late G1 phase of 2i FUCCI ESCs only hypo-phosporylated RB is detected (Figure 1G). These results were 
confirmed in G1-phase sorted Suv39h WT ESCs14 and in E14 ESCs (Figure S2F and data not shown). 
Phosphorylated RB is, however, present in S-/G2-phase in both 2i and serum ESCs (Figure 1G and S2F). 
In P21/P27 DKO ESCs cultured in 2i, the hypo-phosphorylated form of RB is hardly detected. This indicates 
that the expression of CDK-inhibitors in 2i prevents phosphorylation of RB (Figure S2G). Besides hypo-
phosphorylated RB, P107 protein levels are higher in 2i ESCs which could aid in reinstating the G1 
checkpoint (Figure S2H). Together, these results suggest that E2F-activity is higher in serum and that E2F 
activity is inhibited by hypo-phosphorylated RB family proteins in 2i. 
We used RB KO and RB/P107/P130 triple knock out (TKO) ESCs15 to corroborate and extend our 
hypothesis that the elongated G1-phase in 2i ESCs is mediated by the RB family proteins. In TKO ESCs, 
the number of cells in G1-phase remains the same when shifting from serum to 2i conditions indicating that 
the RB family proteins are essential for elongation of G1-phase in 2i ESCs (Figure 1H). In 2i ESCs, the cell 
cycle distribution of only RB KO cells is changed, but to a lesser extent than in 2i TKO ESCs (Figure S2I). 
Note that the expression of key pluripotency genes and colony formation is not affected in TKO ESCs 
(Figure S2J and S2K). Taken together, the RB family proteins are involved in the control of the G1-phase 
in 2i ESCs. 
To determine which signaling pathway regulates the phosphorylation status of RB, ESCs were cultured in 
medium + LIF supplemented either with PD0325901 (“PD”), CHIR99021 (“Chiron”) or both (“2i”). When 
taken of 2i ESCs do proliferate for at least 1-2 weeks in Ndiff 227 media (Takara, formerly Ndiff N2B27 – 
StemCells) + LIF. FUCCI reporter assays and PI FACS analysis indicate that the addition of PD, which 
blocks the ERK-signaling pathway, drives the elongation of G1-phase whereas the GSK3-inhibitor Chiron 
has no effect (Figure 2A-C). Western Blot analysis detected hypo-phosphorylated RB only in ESCs cultured 
in the presence of PD (Figure 2D). Similarly, PD addition to serum ESCs gives rise to elevated, mostly 
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hypo-phosphorylated RB protein (Figure 2E and S2F), possibly because of lowered cyclin D levels (Figure 
S2L). These effects are accompanied by an increased number of cells in the G1-phase in wild type ESCs 
(Figure 2F and S2M), which is strongly reduced in TKO ESCs (Figure 2F). Chiron had again only a marginal 
effect on the length of G1 phase in serum ESCs as in serum free conditions (Figure S2M and Figure 2B). 
We conclude that pluripotent 2i ESCs do possess an active G1 restriction point that in serum ESCs is 
abrogated by ERK signaling and RB hyper-phosphorylation. 
It has recently been shown that inhibition of C-MYC and N-MYC in 2i ESCs results in quiescence, mimicking 
in vivo diapause16. To test whether the RB family proteins are required for G1-arrest, we treated WT and 
RB/P107/P130 TKO ESCs with the MYC-inhibitor (MYCi). Upon MYC inhibition, WT 2i ESCs stall in the 
G1-phase in line with a recent report16. In RB/P107/P130 TKO ESCs, however, the number of cells in G1-
phase did not significantly increase upon MYC inhibition (Figure 2G). We conclude that the RB/P107/P130-
mediated restriction point is required to stall the cells in G1 in a dormancy-like state.   
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It has been postulated that an abbreviated G1-phase is characteristic of ESCs and ensures maintenance 
of pluripotency. Our study shows that elongation of the G1-phase in 2i ESCs is the most prominent 
difference in the cell cycle when compared to serum ESCs and yet 2i ESCs are highly pluripotent and 
perform even better in chimera formation then serum ESCs17. Together with the observations that 2i ESCs 
have a lower propensity to differentiate3,18, our findings imply that a short G1-phase is not an intrinsic 
property of pluripotent ESCs. Our data corroborate and significantly extend previous observations in serum 
ESCs19,20, by revealing the mechanism of the fundamentally different G1 control in 2i versus serum ESCs. 
The FGF/ERK signaling plays an important role during early embryonic development and loss of FGF4 
results in impaired cell proliferation of ICM cells (reviewed in Lanner, F. & Rossant, J.21 and Dorey, K. & 
Amaya, E.22). Our results indicate that signaling via the ERK pathway results in a decrease in hypo-
phosphorylated RB, loss of the restriction point and an abbreviated G1-phase in serum ESCs. As the 
FGF/ERK pathway plays a crucial role in early fate-specification during the implantation stage21 that 
coincides with bursts of cell proliferation23, we lend further support to the model in which 2i ESCs resemble 
naive pluripotent (ICM) cells by showing that FGF/ERK signaling results in shortening of G1-phase in 
epiblast (serum) ESCs.  
Besides the difference in G1-phase between serum and 2i ESCs, a shortening of S/G2-phase was observed 
as well. These observations are in concordance with marked changes in cell cycle during early embryonic 
development (reviewed by Duronio, R. J.24 and Bouldin, C. M. & Kimelman, D.25). It is tempting to speculate 
that this is caused by observed discrepancies in the expression of cell cycle regulators, such as differences 
in Cyclin E expression during S-phase and the higher expression of all Cdc25 isoforms during G2-phase 
(unpublished data)25–27. Moreover, differences in epigenetic make up and chromatin landscape between 
serum and 2i ESCs28,29 could possibly affect the length of these phases as well30. 
Figure 2. Role of ERK signaling and RB family proteins in cell cycle regulation in ground state 
ESCs. (A) Quantification of G1- and SG2-phases in FUCCI cells in Ndiff medium supplemented with 
LIF and either PD, Chiron or both inhibitors. (B) FUCCI reporter expression shows that inhibition of the 
ERK signaling pathway by PD results in elongation of G1-phase. Significance was assessed by a two-
tailed Student’s T test, *p-val<0.05.  At least two independent experiments showed these results. (C) 
Cell cycle analysis using PI shows that the addition of PD results in an increase of cells in G1-phase, 
whereas Chiron had no significant effect (Student’s T-test, *p-val<0.05). (D) ESCs cultured in serum 
free NDiff medium + LIF supplemented with either one or both inhibitors shows the presence of hypo-
phosphorylated RB upon inhibition of the ERK signaling pathway by PD and not by Chiron. (E) Exposure 
of serum ESCs to PD results in hypo-phosphorylated and increased expression of RB. Similar results 
were observed in two independent experiments. (F) Quantitation of the number of cells in G1-phase of 
WT serum ESCs and RB/P107/P130 triple knock out serum ESCs incubated in the presence of PD 
showing that elongation of G1-phase required the RB family proteins. Bar graphs indicate the mean ± 
SD. Comparison was performed by two-tailed Student’s T-test, *p-val < 0.01; **p-val < 0.001; n = 3. (G) 
Inhibition of MYC by a small molecule inhibitor, 10058-F4, results in a near complete block of WT ESC 
but not of RB/P107/P130 triple knock out ESCs cultured in 2i. Error bars are means ± SD from 
triplicates, representative of two independent experiments. Significance was assessed by two-tailed 
Student’s T-test, *p-val <0.001, **p-val < 0.0001. See also Figure S2. The bar charts represent the 
means ± SD. 
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Collectively, our results provide a paradigm shift in how the cell cycle is regulated in pluripotent stem cells. 
Surprisingly, 2i ESCs do harbor an intact G1 control, which is lost upon adaptation to serum conditions due 
to increased ERK signaling and RB hyper-phosphorylation. Our data implies a revised conceptual 
framework for cell cycle regulation in pluripotent ESCs and during early embryonic development. 
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Figure S1 related to figure 1. G1-phase is elongated in 2i ESCs and is accompanied by lowered 
E2F activity and reduced expression of genes involved in S-phase entry. (A) Cell cycle analysis 
using BrdU/PI of WT 2i R1 ESCs upon adaptation to serum conditions. (B) Expression analysis using 
RT-qPCR on pluripotency, serum-specific and 2i-specific genes upon adaptation of serum ESCs to 2i 
for 48 hours. (C) Quantification of distribution of fully adapted serum and 2i iPS cells over the different 
phases of the cell cycle (Student’s T-test, *p-val<0.05). (D) Karyotype analysis (sequencing of genomic 
DNA) of two cell lines (EB5 and E14) and one WT iPS line. EB5 and iPS line display a normal karyotype 
whereas E14 shows trisomy at chromosome 6 and 8. Shown is the distribution of all sequence tags 
from genomic DNA of indicated cell lines over chromosomes compared to the karyotypic-normal TNG-
A ESC line3. (E) Cell cycle analysis on Nanog- and Nanog+ serum ESCs using Hoechst. Overlay 
histogram showing DNA content from both populations as indicated by gates in the dot plot (grey line 
Nanog- and green line Nanog+). Numbers represent means ± standard deviations from triplicates. The 
experiment has been performed twice showing similar results. (F) Determination of DNA content of 2i 
FUCCI ESCs using vibrant violet staining. Colored lines indicate DNA content of the cell populations 
sorted as indicated in dot plot. (G) Dot plot and histogram of FUCCI reporter expression in serum and 
2i ESCs. Indicated are the mean fluorescence intensities and standard deviations of triplicates. At least 
two independent experiments were performed showing similar results. Student’s T-test, **p-val<0.001, 
*p-val<0.05. (H) Growth curves and doubling times of fully adapted E14 serum and 2i ESCs. For both 
conditions 1.5∙105 cells were seeded in triplicates and aliquots were counted at indicated times and 
presented as means ± SD. Two independent experiments showed similar results. (I) Ratio of gene 
transcription in serum ESCs versus 2i ESCs in late G1-phase using two biological replicates. (J) GO 
analysis on differentially expressed genes in serum ESCs versus 2i ESCs in late G1-phase. (K) 
Boxplots of RNA expression (log2 RPKM) of histone and random chosen genes in late G1-phase 
showing lower expression of histone genes in 2i ESCs compared to serum. Statistical analysis was 
performed using the paired two tailed Student’s T-test, *p-val <0.001. (L) Motif enrichment analysis 
using Homer on promoter regions of genes higher expressed in serum ESCs. (M) Expression values 
(RPKM) of known E2F target genes clustered based on function. (N) ChIP-seq analysis of E2F1 
occupancy is highly correlated between serum and 2i (R2 = 0.79). The location of the E2F1 binding 
sites is presented as a PIE diagram: The majority of peaks is located in either the promoter-TSS or the 
5’UTR and ~5% shows differential E2F1 occupancy between serum and 2i (Log2-fold change > 1, p-
val <0.05). Lower panel: correlation analysis revealing absence of a correlation (R2= 0.08) between 
differential E2F1 occupancy in ChIP-seq and RNA expression (RNA-seq) suggests that E2F binding 
does not drive the differential gene expression. All values represent the mean ± SD. 
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STAR Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the Lead Contact, Henk Stunnenberg (h.stunnenberg@ncmls.ru.nl). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell lines and culture conditions 
All ESC lines, described including sex in Supplemental Table S1, were cultured in either serum medium, 
containing 15% fetal calf serum (Hyclone), penicillin/streptomycin, sodium pyruvate, 0.1mM 2-
mercaptoethanol, and 1000 U/mL LIF or Ndiff 227 medium (Takara, formerly Ndiff B2N27 - StemCells), 
supplemented with CHIR99021 at 3 mM(Axon), PD0325901 at 1mM(Axon) and 1000 U/mL LIF (Millipore) 
(“2i”) in a 37°C humidified incubator with 5% CO2. Prior to transition from serum medium to 2i medium or 
vice versa cells were washed twice with PBS. 
Figure S2 related to figure 1. The elevated expression of the CDK-inhibitors P21 and P27, hypo-
phosphorylation of RB and increased number of cells in G1-phase in 2i as compared to serum 
ESCs. (A) RNA levels of CDK-inhibitors during early embryonic development in fragments per kilobase 
of exon per million fragments mapped (FPKM), adapted from 11 
(https://doi.org/10.1016/j.devcel.2015.10.011). (B) Western blot analysis of P21, P27 in WT, single and 
combined KO ESCs fully adapted to 2i. (C) Expression of the FUCCI reporters in WT and P21/P27 DKO 
2i ESCs indicates that combined knock out of P21 and P27 results in shortening of G1-phase (Student’s 
T-test, *p-val<0.1∙10-3). (D) Quantitation of Flow cytometry analysis using BrdU/PI showing a significant 
decrease in G1-phase (Student’s T-test, *p-val<0.05) of P21/P27 DKO as compared to WT 2i ESCs. 
No significant changes were observed in P21 KO or P27 KO 2i ESCs compared to WT 2i ESCs. 
Experiment performed in triplicate, using two independent P21 KO clones, three independent P27 KO 
clones and three independent P21/P27 DKO clones. (E) Phosphatase treatment confirmed that the 
lower band present in 2i ESCs is hypo-phosphorylated RB. (F) The Suv39h WT ESC line 14 shows an 
elevated level of hypo-phosphorylated RB in G1-phase both in 2i as well as in serum plus PD0325901 
(hereafter PD) conditions. (G) Western blot analysis phosphorylation of RB in P21/P27 DKO 2i ESCs 
compared to WT 2i ESCs. Two independent clones were assessed showing similar results. (H) Western 
blot analysis showing higher levels of P107 in 2i versus serum ESCs both in total cell lysates and lysates 
from G1-sorted cells. (I) Cell cycle analysis using BrdU/PI on RB KO and RB/P107/P130 TKO ESCs 
grown in 2i. A two-tailed Student’s T-test was used to assess significance of the differences (*p-
val<0.05). (J) Expression levels of pluripotency genes in RB/P107/P130 TKO ESCs  cultured in 2i and 
serum conditions. (K) Colony formation assay as described by 31 performed in triplicate. (L) Western 
blot analysis and its quantitation of cyclin D protein in cell lysate from G1-phase sorted cells cultured in 
serum plus minus the PD inhibitor. (M) Quantitation of the distribution of serum cells upon adaptation to 
serum, serum plus PD, serum plus CHIR90221 (hereafter Chiron), serum plus PD and Chiron or 2i 
medium as assessed by BrdU/PI staining. Significance was tested using a two-tailed Student’s T-test, 
*p-val<0.05. Bar charts and error bars represent the mean ± SD. 
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METHOD DETAILS 
Establishment of R1 FUCCI ESCs 
mKO2-CDT1 (30-120) and AZ1-GEMININ (1-110) gene fragments were PCR amplified from 100 ng 
pcDNA3 backbone (gift from Miyawaki and colleagues 8) using modified T7 and SP6 primers with EcoR1 
restriction sites at their 5’-ends. PCR amplification was performed using Platinum Pfx DNA polymerase 
(Invitrogen) according to manufacturer protocol. After purification using the PCR purification Kit (Qiagen) 
these amplicons were digested with EcoR1 (NEB) according to manufacturer guidelines for 8 hours at 37°C. 
In addition, 5 µg expression vector containing the pCAG promoter and either the puromycin or the neomycin 
selection marker (a gift from Austin Smith and colleagues), was digested and treated with calf intestinal 
phosphatase (NEB). Next, the inserts and the expression plasmids were verified and purified by gel 
electrophoresis. The mKO2-CDT1 (30-110) fragment was ligated into pCAG-IRES-PURO and the AZ1-
GEMININ (1-110) into pCAG-IRES-NEO expression plasmid overnight at 16°C using the DNA Ligation 
Mighty Mix Kit (Takara). The ligation products were transformed into DH5α E. Coli and plated onto agar 
plates containing carbenicillin (100 µg/mL). Next day colonies were picked and DNA was sent for 
sequencing. Clones of interest were amplified in LB containing  carbenicillin (100 µg/mL) and DNA was 
isolated using the HP Endotoxin-free Maxi Prep kit (Sigma). For transfection, we used a two-step 
transfection selection strategy. First, pCAG-CDT1-PURO was transfected in mouse R1 ESCs and selected 
with puromycin (1 µg/ml) for approximately 2 weeks, and stable cell lines were isolated. Next, pCAG-
GEMININ-NEO was transfected into the cell lines, and selected with G418 (200 µg/ml) for 2 weeks, and 
stable lines were isolated. 
Western Blot 
Cells were lysed in RIPA buffer with fresh cOmplete, EDTA-free protease inhibitor Cocktail (Roche) and 
PhosSTOP (Roche). Cell extracts were separated by SDS– PAGE and then transferred to nitrocellulose 
membranes in 20 mM Tris- HCl [pH 8.0], 150mM glycine, 20% (v/v)d methanol. Membranes were blocked 
with 5% (w/v) nonfat dry milk in Tris-buffered saline with Tween 20 (TBST; 20 mM Tris-HCl [pH 7.6], 0.1% 
Tween 20, 137 mM NaCl), incubated with primary antibodies, then secondary antibodies, and detected with 
ECL reagents (Amersham Biosciences). 
Flow cytometry 
The BD FACS Aria cell sorter was used to analyze and sort FUCCi ESCs. For cell cycle analysis cells were 
pulsed with 20 µM BrdU for 30 minutes, harvested by trypsinisation and fixed over night in 70% ethanol at 
4°C. After denaturation of the DNA using 2N HCl + 0.5% Triton-X100 for 30 minutes at room temperature, 
neutralization with 0.1M Na2B4O7 (pH 8.5), samples were incubated with the anti-BrdU antibody over night 
at 4°C. Next day, the samples were stained with Propidium Iodide staining solution (10 ug/ml PI [Sigma, 
P4170] and 0.2mg/mL RNAse A in PBS) over night at 4°C. Samples of at least 10000 cells were acquired 
using a FACScalibur flow cytometre (Becton Dickinson). Subsequent analysis was done with Flowing 
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Software. For the cell cycle analysis of Nanog-GFP ESCs cells were incubated with Hoechst 33342 
(Invitrogen) for one hour at 37°C and analyzed on the BD FACS Aria. 
Colony formation assay 
Serum grown ESCs were seeded at a dilution of one cell per well into 96-well plates using the BD FACS 
Aria, as described in 31, containing either serum or 2i medium. The cells were cultured for two weeks and 
the number of colonies was assessed in a blind manner.  
ChIP-seq 
Serum and 2i ESCs were fixed using 1% PFA for 10 min at room temperature. Subsequently, fixation was 
quenched by adding 1.25M glycine to a final concentration of 0.125M. After sonication the material of 4-5 
million cells and 5 µL E2F1 antibody were used per ChIP. ChIP enrichment was assessed by qPCR and 
2ng of DNA was used for library construction. Paired-end 43bp deep sequencing was performed using 
Illumina’s NextSeq 500 sequencer. 
Karyotype Analysis 
For karyotype analysis chromatin of 0.5 million cells was sonicated and decrosslinked over night. Next 
genomic DNA was purified and used for library construction. Paired-end 43bp deep sequencing was 
performed using Illumina’s NextSeq 500 sequencer. Reads were mapped using BWA and unique reads 
per chromosome were normalized by total reads. 
RNA-seq 
Cells were sorted and total RNA was extracted using Trizol (Life Technologies) according to manufacturer’s 
instructions. After DNAse treatment, 5 µg of extracted RNA was depleted from ribosomal RNA using Ribo-
Zero Gold Kit (Epicentre Madison, Winsconsin, USA). After fragmentation of the rRNA-depleted RNA, 
500ng was reverse-transcribed using Super Script III Reverse Transcriptase (Invitrogen) and random 
primers (Invitrogen) following the manufacturer’s instructions. Next, libraries were prepared using the 
TruSeq RNA Sample Prep Kit (Illumina) following the manufacturer’s instructions. Libraries were indexed 
using NEXTflex adapters (Bioo- Scientific Corporation, Austin, TX, USA), and the quality was assessed by 
qPCR and Bioanalyzer (BioRad). Single-end 43bp deep sequencing was performed on Illumina instruments 
using TruSeq reagents (Illumina, San Diego, CA, USA), according to manufacturer’s instructions. 
Genome editing with CRISPR-Cas9 
CRISPR-Cas9 gene editing was used to knock out cdkn1a (P21) and cdkn1b (P27). In brief, gRNAs were 
designed using the online tool (crispr.mit.edu) and cloned into the plasmid Cas9(BB)-2A-GFP (Addgene 
plasmid 48138) using the Bpi1 restriction sites as described previously32. FUCCI serum ESCs were 
transfected using lipofectamine-LTX (life technologies). After 48 h, GFP+ cells were sorted with a BD FACS 
Aria. Cells were split at clonal density and after approximately 7 days colonies were picked for expansion. 
Genomic DNA from individual clones was extracted using the Wizard Genomic DNA extraction kit. The 
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targeted region was PCR amplified and Sanger Sequenced. gRNA oligonucleotides were as follows: 
Cdkn1a-01_Fwd: CACCGTTGTCTCTTCGGTCCCG, Cdkn1a-01_Rev: 
AAACCGGGACCGAAGAGACAAC, Cdkn1a-02_Fwd: CACCGTCCGACCTGTTCCGCAC, Cdkn1a-
02_Rev: AAACGTGCGGAACAGGTCGGAC Cdkn1b_Fwd: CACCGCGGATGGACGCCAGACAAG, 
Cdkn1b_Rev: AAACCTTGTCTGGCGTCCATCCGC. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Bar charts represent the mean ± standard deviation of the mean (SD). When comparing two conditions, 
statistical differences were assessed in Microsoft Excel with  a paired two-tailed Student’s T test unless 
otherwise indicated in the legends. A p-value of < 0.05 was considered significant unless stated differently 
and the exact degree of significance as indicated by asterisks is stated in the legends. Pie charts display 
the means of an experiment performed in triplicate representative for at least two independent experiments. 
Quantification and statistics belonging to the pie charts are included in the figure or Supplemental Table 
S1. 
DATA AND SOFTWARE AVAILABILITY 
Software 
BWA and bowtie were used for ChIP-seq and RNA-seq, respectively, to align sequencing reads to the 
mouse genome (mm9) using default parameters. For RNA-seq transcript quantification was performed 
using the MMSeq package and after setting a threshold of at least 50 reads over the gene body in either 
serum or 2i the DESeq2-package was used to call differentially expressed genes (log2-fold change >1 and 
a p-value < 0.05)33. Normalized read counts were subsequently used to calculate RPKM values. For ChIP-
seq picard tools was used to remove duplicates (http:/broadinstitute.github.io/picard) and the Encode 
blacklist was used to filter out artifact regions34. Next, macs2 was used to call peaks in individual files and 
bedtools was used to intersect the peak-files of biological replicates. The peak-files of serum and 2i were 
merged using bedtools and reads over the genomic regions in resulting file were counted using bedtools 
multicov. The DESeq2-package was used to call differential peaks (log2-fold change >1 and a p-value < 
0.05).  GO-term analysis was performed with DAVID (http:// david.abcc.ncifcrf.gov/). Homer software was 
utilized to find de novo enriched motifs in the promoters of differentially expressed genes using default 
settings.  
Data resources 
The accession number for the RNA-seq data of serum and 2i ESCs in G1-phase as well as the E2F1 ChIP-
seq data reported in this paper is Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) Database: 
GSE85690. The original unprocessed data is available through a Mendeley Database: 
http://dx.doi.org/10.17632/9hcdttwzyb.1. 
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Summary 
In somatic cells P53 is involved in a plethora of regulatory pathways that act upon different types 
of stress and result in cell cycle arrest. On the contrary, in mouse Embryonic Stem Cells (ESCs) 
grown in serum-rich conditions the role of P53 in facilitating G1-phase arrest upon DNA damage 
has been reported to be compromised. Here we provide evidence that P53 modulates G1-phase 
progression upon transition of naive serum ESCs to their ground state. The expression of hypo-
phosphorylated RB and elongation of G1-phase characteristic to ground state ESCs is dependent 
on P53.  Moreover, in contrast to serum ESCs ground state ESCs accumulate in G1-phase upon 
induction of DNA damage suggesting that P53 elicits the DNA damage response pathway in ground 
state but not in serum ESCs. Furthermore, transcriptome analysis reveals that P53 activity induces 
the expression genes involved in early developmental processes specifically in ground state ESCs. 
Together, these findings suggest that P53 is active in ground state ESCs and that its activity is 
abolished in serum ESCs. 
Introduction 
Compared to somatic cells the cell cycle of mouse Embryonic Stem Cells (ESCs) cultured in the presence 
of serum and LIF is extremely short, mainly due to short Gap- (G-) phases. In particular the gap phase 
between mitosis and DNA replication, G1-phase, is very short in these mouse ESCs1. The continuous 
activity of Cyclin Dependent Kinases (CDKs), mainly CDK2, results in constitutively hyper-phosphorylated 
inactive RB and consequently in high E2F transcription factor activity and rapid progression into S-phase2. 
On the other hand, proteins that delay G1-progression, e.g. the CDK2-inhibitors P21 and P27, are not 
expressed in ESCs2–5. Because a key function of G1-phase is to ensure genome integrity prior to DNA 
replication these observations have raised questions about DNA damage response in ESCs. In particular, 
ESCs will give rise to the germline and mutations acquired in the early embryo will therefore be passed on 
to its progeny, stressing the importance of DNA damage control in the early embryo. The fact that 
spontaneous mutations occur at much lower frequency in ESCs when compared to somatic cells (1/106 
versus 1/104, respectively) suggests that ESCs have employed alternative ways to cope with DNA 
damage6. In somatic cells, DNA damage response pathways that are active during G1-phase induce either 
apoptosis or G1-arrest, thereby preventing progression into S-phase. Interestingly, ESCs do in contrast to 
somatic cells not go into G1 arrest upon DNA damaging treatments7,8.  
Bypass of the G1 checkpoint in ESCs has been attributed to high levels of the CDK2 activator CDC25A9 
and the lack of a P53-mediated DNA damage response7,10. P53 is the most frequently mutated gene in 
cancer11 and plays a pivotal role in DNA damage induced stress responses. Activated P53 can induce 
either apoptosis, via canonical Bak / Bax, or induce a G1-arrest via its downstream effector P2112. The 
response of ESCs to treatment with anti-metabolites or ionizing radiation was similar to Mouse Embryonic 
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Fibroblasts (MEFs) that lacked P53, in that they both progressed into S-phase. Despite phosphorylation 
and activation of P53 upon irradiation, no increase in P21 protein levels was observed in ESCs10. Some 
studies have suggested that the lack of a functional P53/P21 DNA damage response is the result of 
cytoplasmic localization and inefficient translocation to the nucleus of P53 or the activity of micro RNAs7,13. 
More recent studies have however indicated that proteosomal degradation of P21 inhibits the accumulation 
of P21 protein upon DNA damage and thereby prevents induction of G1-arrest8. 
Although the P53-mediated DNA damage response pathways seems to be abolished in in ESCs in vivo 
data has indicated that P53 is active in the Inner Cell Mass (ICM) during early embryonic development14. 
These observations are in line with growing evidence that P53 plays in important role in embryonic 
development and differentiation. The exact role of P53 in embryonic development is however still unclear. 
Although P53 is highly expressed in the early embryo, P53 null mutant mice do not show developmental 
defects, strongly suggesting that P53 is not essential for embryonic development15. However, other studies 
have shown that loss of P53 can result in subtle developmental defects (reviewed by Shin, M. H., He, Y. & 
Huang, J.16) and that P53 is essential for normal embryonic development in Xenopus laevis17. These 
seemingly contradictory results could be due to the functional redundancy of P53 with its family members 
P63 and P7318,19. More recent studies in ESCs have shown that P53 plays an important role in the regulation 
of developmental genes during differentiation20 and that P53 orchestrates mesoderm differentiation by 
modulating Wnt signaling21. Interestingly, a role of P53 in stem cell maintenance has also reported in the 
literature, either by regulating Wnt signaling22 or by enhancing TGF-β signaling23. Together these reports 
indicate that the function of P53 depends on the cellular state and its environmental factors. 
Although ESCs are classically cultured in the presence of serum, in the last decade new culture conditions 
have been developed24,25. Studies on the epigenome, transcriptome have revealed that these culture 
conditions give rise to different flavors of ESCs reflecting different developmental stages5,26. In this regard, 
we have previously shown that the short G1-phase is characteristic to naive serum ESCs and is the result 
of ERK signaling. The latter pathway is inhibited in ground state ESCs cultured in serum-free 2i conditions 
leading to an elongated G1-phase3. Because the shortened G1 is accompanied by abrogated DNA damage 
response pathways these observations imply reactivation of DNA damage response pathways in 2i ESCs. 
Therefore, we set out to decipher the role of P53 in ground state 2i conditions. To gain a better 
understanding of the role of P53 in 2i conditions we have deleted P53 in a mouse ESC cell line expressing 
the FUCCI reporters. These reporters allow the designation of cells throughout the different phases of the 
cell cycle and subsequent analysis of specific populations. The data presented here imply that the function 
of P53 is compromised during the abbreviated G1-phase in naive serum ESCs and that P53 is plays a role 
in G1-phase progression in ground state 2i ESCs. Moreover, data on genome-wide P53 binding and the 
transcriptome of P53-/- 2i ESCs suggests that P53 regulates the expression of developmental genes in 
ground state ESCs. 
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Results 
P53 regulates G1-phase progression in 2i ESCs 
Our previous studies revealed lengthening of G1-phase in ground state 2i ESCs when compared to naive 
serum ESCs. Moreover, an increase in the expression of several Cyclin-Dependent Kinase (CDK)-inhibitors 
(CDKi), among which the P53-target gene Cdkn1a (coding for P21), during G1-phase was observed in 
ground state 2i ESCs3,5. The deletion of P21 resulted however only a minor effect on the cell cycle of 2i 
ESCs (Figure 1A and ter Huurne, M.3). To assess the effect on gene expression we sorted WT and P21-/- 
2i ESCs in G1-phase and performed whole genome RNA-seq. In line with the limited effect on the cell cycle, 
only a small set of genes (~0.2%) was either significantly up- or down-regulated (Log2-fold Change > 1 or 
< -1, Adjusted P-value <0.05). The deletion of P21 did however result in a moderate increase in the 
expression of genes involved in chromatin assembly, mainly histone genes, suggesting that P21 does 
prevent the induction of DNA replication to some extent (Figure 1B). Accordingly, the combined deletion of 
Cdkn1a and Cdkn1b, coding for P27, resulted in shortening of G1-phase3, indicating that these proteins 
prevent S-phase entry in 2i ESCs. The elevated expression of P21 and elongated G1-phase led us to 
hypothesize that P53 activity is increased in 2i ESCs and contributes to cell cycle regulation of ground state 
ESCs. Although previous studies have not identified Trp53 as being differentially expressed between serum 
and 2i ESCs3,5 P53 binding and activity is regulated by several phosphorylation and acetylation events27,28. 
Quantification of P53 protein levels in several fractions of the cell indicated that the level of chromatin-
bound P53 is higher in ground state 2i ESCs when compared to naive serum ESCs (Figure 1C). To 
determine whether the expression of P21 is dependent on P53 we used the Crispr-Cas gene editing system 
to create three independent P53-/- clones in R1 ESCs that express the FUCCI reporter constructs (Figure 
1D). Western blot analysis showed successful targeting of P53 as well as a decrease in P21 levels in 2i 
P53-/- ESCs (Figure 1E)29. 
To determine the effect of P53 deletion on the cell cycle we next measured the expression of the FUCCI 
reporters. As we reported previously the number of the WT 2i ESCs in late G1-phase was much higher 
when compared to WT serum ESCs30. Upon deletion of P53 there was however a dramatic decrease in the 
number of 2i ESCs in late G1-phase (Figure 1F and 1G). Serum ESCs enter S-phase prematurely and 
therefor lack cells in late G1-phase. Accordingly, virtually no effect on the cell cycle was observed in P53-/- 
serum ESCs. We next made use of an independent P53-/- cell line to assess the distribution of cells over 
the different phases of the cell cycle using BrdU / PI staining20. In 2i conditions the number of cells in G1-
phase was significantly lower in P53-/- ESCs when compared to WT, confirming our previous observations. 
Again no effect of loss of P53 was observed in serum ESCs (Figure 1H). Because P21 is primarily 
expressed during G1-phase in 2i ESCs 3 the decreased expression in P53-/- ESCs could also be the result 
of the diminished number of cells in G1-phase. A western blot on G1-phase sorted cells shows however 
that the expression of P21 is lowered specifically in 2i G1-phase cells (Figure 1I). Together these results 
suggest that P53 regulates P21 expression and G1-phase progression in ground state 2i ESCs whereas it 
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has a minor role in serum ESCs. To test whether the P53/P21-mediated DNA damage checkpoint is 
activated in 2i cells we used doxorubicin to induce DNA damage in serum and 2i ESCs. As expected, we 
did not observe an increase in the number of serum cells in G1-phase upon doxorubicin treatment due to 
the lack of the G1-checkpoint10. In 2i cells however an increase in the number of cells in G1 was observed, 
suggesting that these cells have an activated DNA damage response pathway (Figure 1J). 
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Genes involved in cell cycle arrest and apoptosis are downregulated upon deletion of 
P53 in ground state 2i and serum ESCs 
To determine the impact of loss of P53 on the transcriptome of serum and 2i ESCs we performed RNA-seq 
on G1-phase sorted WT and P53-/- ESCs in serum and 2i. The PCA plot in figure 2A shows that the variation 
between WT and P53-/- is larger in 2i conditions when compared to serum conditions (Figure 2A). In 
addition, the percentage of differentially expressed genes between WT and P53-/- ESCs was higher in 2i 
when compared to serum (Figure 2B). Although the cell cycle of P53-/- serum ESCs was hardly affected, 
genes lower expressed in these cells when compared to WT cells were involved in apoptosis and cell cycle 
arrest both in serum as well as 2i (Figure 2C). Surprisingly, genes that showed lowered expression in 2i 
P53-/- ESCs when compared to 2i WT ESCs specifically were not only involved in DNA response but also 
in developmental processes (Figure 2D). Although previous reports have described a role of P53 upon 
differentiation, this is the first time that such an effect is observed in pluripotent ESCs, suggesting that 
serum conditions conceal this function of P53 in ESCs. Although P53 has been shown to be able to drive 
differentiation by inhibiting the expression of Nanog31, we did not observe an increase in the expression of 
Nanog in 2i nor in serum P53-/- ESCs (Figure 2E). These findings are consistent with a previous report 
showing no effect of loss of P53 on Nanog expression20. 
Figure 01: P53 is essential for the elongated G1-phase in 2i ESCs. (A) FUCCI reporter expression 
in WT and P21-/- 2i ESCs showing only minor differences in the distribution of cells in G1- and S-/G2- 
phase. (B) The transcriptome of P21-/- 2i ESCs displays increased expression of genes involved in 
nucleosome assembly and DNA packaging. (C) Higher P53 protein levels are observed in the nuclear 
fraction as well as on the chromatin in 2i ESCs when compared to serum ESCs. (D + E) Construction 
of P53-/- R1 FUCCI ESCs and a WB on P53 and P21 in three independent P53-/- clones in 2i. (F) When 
compared to WT the P53-/- ESCs have lowered expression of the G1-phase specific FUCCI reporter in 
2i. In serum no differences between WT and P53-/- ESCs are observed. (G) Quantification of the G1-
phase reporter expression using three independent P53-/- clones in serum and 2i. For WT two biological 
replicates were used. (H) Quantification of WT and P53-/- EB5 cells over the different phases of the cell 
cycle using Bromo-deoxy-Uridine (BrdU) incorporation combined with Propidium Iodide (PI) staining. (I) 
WB on P21 showing decreased expression of P21 during G1-phase in P53-/- ESCs. Significance was 
assessed using a two-tailed students T-test, * P-value < 0.05. (J) The doxycycline treatment of 2i ESCs 
results in an increase in the relative amount of cells in G1-phase whereas only an increase in number 
of G2-phase cells is observed in serum ESCs. 
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The pocket proteins Rb and P130 are direct transcriptional targets of P53 
The most prominent difference between WT and P53-/- 2i ESCs is the shortened G1-phase in P53-/- cells, 
resembling the G1-phase of WT serum ESCs. Although the expression of P21 is lowered in P53-/- 2i ESCs 
we did not observe lowered expression of the CDK-inhibitor Cdkn1b (P27) (Figure 3A). Since deletion of 
P21 alone has only a minor effect on the cell cycle (Figure 1A and3) these results suggest that the shortened 
G1-phase as the result of loss of P53 is mediated via other cell cycle regulators. We therefore examined 
the expression of other genes involved in G1-phase progression (Figure 3A). The downstream targets of 
the CDK/CYCLIN pathway are the pocket proteins RB, P107 and P130. The abbreviated G1-phase in 
serum ESCs is characterized by hyper-phosphorylated and therefor inactive RB. Inhibition of the ERK-
signaling pathway however results in lowered CYCLIN-D levels, the appearance of hypo-phosphorylated 
Figure 2: Deletion of P53 results in lowered expression of genes involved in apoptosis and 
organismal development in 2i ESCs. (A) Principal Component Analysis on gene expression in WT 
and P53-/- ESCs in serum and in 2i. (B) The number of genes differentially expressed between WT and 
P53-/- ESCs is higher in 2i than in serum conditions. (C) Gene Ontology analysis revealing lowered 
expression of genes involved in apoptosis and development upon deletion of P53 in 2i ESCs. (D) Genes 
involved in organismal and tissue development are specifically downregulated in P53-/- ESCs in 2i 
conditions. (E) Table containing the expression values of genes involved in tissue development that are 
down-regulated in P53-/- 2i ESCs. 
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RB and reinstatement of the G1-checkpoint in 2i ESCs3. The pocket proteins, among others RB and P130, 
control G1-phase progression in 2i ESCs by inhibiting the E2F transcription factors3.   
In P53-/- ESCs, both Rb1 and Rbl2 (coding for RB and P130, respectively) RNA levels are decreased when 
compared to WT ESCs (L2FC -0.88 and -0.76, respectively) (Figure 3B). Since these proteins are active in 
2i but not in serum ESCs this could explain why the effect of deletion of P53 has a much stronger effect in 
2i ESCs when compared to serum ESCs. To assess how P53 regulates the expression of Rb1 we consulted 
ChIP-seq data on P53 in serum ESCs32. In serum and 2i ESCs P53 binds to the Transcriptional Start Site 
(TSS) and gene body of Rb1 and P130, suggesting a direct transcriptional regulation (Figure 3C). In line 
with literature only inactive hyper-phosphorylated RB was expressed in serum ESCs, whereas hyper- as 
well as active hypo-phosphorylated RB was expressed in 2i ESCs3. In both conditions the expression was 
drastically reduced in the P53-/- ESCs (Figure 3D). Since cell cycle distribution of asynchronously growing 
WT and P53-/- 2i ESCs is different, we next determined RB expression levels throughout the cell cycle in 
WT and P53-/- serum and 2i ESCs. Again, a clear reduction of RB expression in P53-/- ESCs was observed 
(Figure 3E). These results suggest that P53 regulates the transcription of the pocket proteins RB and P130 
thereby elongating G1-phase in 2i ESCs. Due to increased ERK-/CDK/Cyclin-signaling RB is constitutively 
hyper-phosphorylated in serum ESCs and the deletion of P53 has hardly any effect in these cells (Figure 
3F). 
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Although our data indicate that loss P53 has a bigger impact on the cell cycle of 2i cells than on that of 
serum ESCs, it remains largely elusive what causes this difference. To our surprise, the expression of P53 
was higher in serum ESCs (L2FC ≈ 1.23, Adjusted P-value < 0.05), suggesting that regulation takes place 
on protein level. Firstly, GSK3 promotes the degradation of P5333 and the elevated activity of P53 in 2i 
might therefor be the result of the inhibition of this pathway by chiron. Secondly, the activity of P53 can be 
influenced by a range of posttranslational modifications, like phosphorylation, acetylation and sumo 
modifications34. The Aurora A kinase that can inhibit P53-activity35 is significantly lower expressed in 2i 
when compared to serum ESCs (L2FC ≈ -1.10, Adjusted Pvalue < 0.05, data not shown), whereas its 
negative regulator is higher expressed in 2i (L2FC ≈ 0.7, data not shown). In addition, Sirt1, a deacetylase 
that has shown to block translocation of P53 into the nucleus in ESCs36, is lower expressed in 2i ESCs 
(L2FC ≈ -1.29, Adjusted Pvalue < 0.05). Together these processes might contribute to the increased activity 
of P53 in 2i ESCs. To what extent these and other mechanisms impact on the role of P53 in 2i ESCs will 
be an interesting subject for future studies. 
Discussion 
Although P53 is highly expressed in ESCs and active in the early embryo its function is still subject of 
debate. Early studies in serum ESCs have suggested that it cannot act as a regulator of G1-phase 
progression due to functional uncoupling of the P53/P21 axe8. We have previously shown that the 
abbreviated G1-phase in serum ESCs is the result of ERK signaling and Rb hyper-phosphorylation3. The 
results presented here suggest that the abbreviated G1-phase in serum ESCs obscures an unexplored 
function of P53 in the cell cycle of ESCs. In ground state 2i ESCs, P53 regulates the expression of P21 and 
the pocket proteins Rb and P130. This function of P53 is required for the elongated G1-phase in 2i 
conditions. These results suggest that in contrast to serum ESCs DNA damage control pathways are 
functional in 2i ESCs 7. On the other hand, the activation of the P53/P21 pathway is possibly the result of 
decreased DNA methylation and lowered genomic integrity in 2i ESCs37. Follow up studies using DNA 
damaging agents are however needed to test whether 2i ESCs are indeed less prone to DNA damage.  
Our findings suggest that in the early embryo where ERK signaling is absent, P53 is plays a role during G1-
phase and to restrict cell proliferation. Interestingly, the cellular senescent state that resembles diapause 
in vivo is dependent on the presence of the pocket proteins3,38. The extension of our observations is that 
Figure 3: P53 regulates G1-phase progression via the expression of the pocket proteins Rb and 
P130. (A) Bar graph showing differential expression of cell cycle regulators in serum and 2i WT and 
P53-/- ESCs during G1-phase. (B) The expression of Rb1 and Rbl2 is down in P53-/- both in serum and 
2i ESCs. *P-value<0.05. (C) ChIP-seq data shows binding of P53 at the Transcriptional Start Site (TSS) 
of Rb. (D) The expression of hyper-phosphorylated Rb and hypo-phosphorylated Rb is reduced in P53-
/- ESCs in serum and 2i, respectively. (E) The expression of Rb is lowered throughout the cell cycle in 
P53-/- ESCs when compared to WT ESCs. (F) Proposed model that displays the differences in cell cycle 
control between serum and 2i WT ESCs (left panel) and the differences between WT and P53-/- ESCs 
in 2i (right panel). 
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P53 plays a role during diapause. Possibly, P53 is highly expressed in early rodent embryos in order to 
induce diapause in response to stressful conditions. 
Besides the differences in cell cycle control between WT and P53-/- 2i ESCs, the RNA-seq data uncovered 
a large number of genes affected by loss of P53 in 2i conditions (Figure 2D). As opposed to serum 
conditions, a significant proportion of the differentially expressed genes between WT and P53-/- ESCs in 2i 
is involved in systems and tissue development. These findings are in line with previous reports that suggest 
an important role of P53 in differentiation, although the underlying mechanisms might not be the same. How 
P53 regulates the expression developmental genes in 2i remains to be determined, possibly the differential 
regulation of pocket proteins plays a role, considering their role in development and differentiation39,40. 
Altogether we show that in ESCs the function of P53 depends on their cellular state. In ground state 2i 
ESCs P53 is involved in cell cycle control and regulates the expression of developmental genes. 
Materials and Methods 
Cell lines and culture conditions 
All ESC lines were cultured in either serum medium, containing 15% fetal calf serum (Hyclone), 
penicillin/streptomycin, sodium pyruvate, 0.1mM 2-mercaptoethanol, and 1000 U/mL LIF or Ndiff 227 
medium (Takara, formerly Ndiff B2N27 - StemCells), supplemented with CHIR99021 at 3 µM (Axon), 
PD0325901 at 1 µM (Axon) and 1000 U/mL LIF (Millipore) (“2i”) in a 37°C humidified incubator with 5% 
CO2. Prior to transition from serum medium to 2i medium or vice versa cells were washed twice with PBS. 
Western Blot 
Cells were lysed in RIPA buffer with fresh cOmplete, EDTA-free protease inhibitor Cocktail (Roche) and 
PhosSTOP (Roche). Cell extracts were separated by SDS– PAGE and then transferred to nitrocellulose 
membranes in 20 mM Tris- HCl [pH 8.0], 150mM glycine, 20% (v/v)d methanol. Membranes were blocked 
with 5% (w/v) nonfat dry milk in Tris-buffered saline with Tween 20 (TBST; 20 mM Tris-HCl [pH 7.6], 0.1% 
Tween 20, 137 mM NaCl), incubated with primary antibodies, then secondary antibodies, and detected with 
ECL reagents (Amersham Biosciences). 
Flow cytometry 
The BD FACS Aria cell sorter was used to analyze and sort FUCCi ESCs. For FUCCI reporter quantification 
CSV files were analyzed using the Flowcore Package. For cell cycle analysis cells were pulsed with 20 µM 
BrdU for 30 minutes, harvested by trypsinisation and fixed over night in 70% ethanol at 4°C. After 
denaturation of the DNA using 2N HCl + 0.5% Triton-X100 for 30 minutes at room temperature, 
neutralization with 0.1M Na2B4O7 (pH 8.5), samples were incubated with the anti-BrdU antibody over night 
at 4°C. Next day, the samples were stained with Propidium Iodide staining solution (10 ug/ml PI [Sigma, 
P4170] and 0.2mg/mL RNAse A in PBS) over night at 4°C. Samples of at least 10000 cells were acquired 
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using a FACScalibur flow cytometre (Becton Dickinson). Subsequent analysis was done with Flowing 
Software. 
ChIP-seq 
Serum and 2i ESCs were fixed using 1% PFA for 10 min at room temperature. Subsequently, fixation was 
quenched by adding 1.25M glycine to a final concentration of 0.125M. After sonication the material of 4-5 
million cells and 5 µL E2F1 antibody were used per ChIP. ChIP enrichment was assessed by qPCR and 
2ng of DNA was used for library construction. Paired-end 43bp deep sequencing was performed using 
Illumina’s NextSeq 500 sequencer. 
RNA-seq 
Cells were sorted and total RNA was extracted using Trizol (Life Technologies) according to manufacturer’s 
instructions. After DNAse treatment, 5 µg of extracted RNA was depleted from ribosomal RNA using Ribo-
Zero Gold Kit (Epicentre Madison, Winsconsin, USA). After fragmentation of the rRNA-depleted RNA, 
500ng was reverse-transcribed using Super Script III Reverse Transcriptase (Invitrogen) and random 
primers (Invitrogen) following the manufacturer’s instructions. Next, libraries were prepared using the 
TruSeq RNA Sample Prep Kit (Illumina) following the manufacturer’s instructions. Libraries were indexed 
using NEXTflex adapters (Bioo- Scientific Corporation, Austin, TX, USA), and the quality was assessed by 
qPCR and Bioanalyzer (BioRad). Paired-end 36bp deep sequencing was performed on Illumina 
instruments using TruSeq reagents (Illumina, San Diego, CA, USA), according to manufacturer’s 
instructions. 
Genome editing using CRISPR-Cas9 
CRISPR-Cas9 gene editing was used to knock out Trp53 (P53). In brief, gRNAs were designed using the 
online tool (crispr.mit.edu) and cloned into the plasmid Cas9(BB)-2A-GFP (Addgene plasmid 48138) using 
the Bpi1 restriction sites as described previously41. FUCCI serum ESCs were transfected using 
lipofectamine-LTX (life technologies). After 48 h, GFP+ cells were sorted with a BD FACS Aria. Cells were 
split at clonal density and after approximately 7 days colonies were picked for expansion. Genomic DNA 
from individual clones was extracted using the Wizard Genomic DNA extraction kit. The targeted region 
was PCR amplified and Sanger Sequenced. gRNA oligonucleotides were as follows: P53_gRNA_Fwd: 
CACCGGAGCTCCTGACACTCGG, P53_gRNA_Rev: AAACCCGAGTGTCAGGAGCTCC. 
Quantification And Statistical Analysis 
For boxplots displaying reporter expression all events of the indicated number of biological replicates were 
combined. Subsequently the different conditions were compared and statistical differences was assessed 
in Microsoft Excel with a two-tailed Student’s T test. Pie charts display the means of an experiment 
performed in triplicate. 
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Software 
BWA and bowtie were used for ChIP-seq and RNA-seq, respectively, to align sequencing reads to the 
mouse genome (mm9) using default parameters. For RNA-seq transcript quantification was performed 
using the MMSeq package and after setting a threshold of an average of at least 5 reads over the gene 
body in all conditions the DESeq2-package was used to call differentially expressed genes (log2-fold 
change >1 and a adjusted p-value < 0.05)42. Normalized read counts were subsequently used to calculate 
RPKM values. 
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Introduction 
Embryonic Stem Cells (ESCs) are subject of intense research. These cells derived from the Inner Cell Mass 
(ICM) of the early blastocyst can be propagated indefinitely in vitro while retaining the transcriptional and 
epigenetic properties of their in vivo counterparts. As a result these in vitro cultured cells maintain the ability 
differentiate into all cells of the fully developed body plan (termed “pluripotent”). Unlimited in vitro expansion 
allows scaling necessary for molecular analysis and has facilitated unraveling the molecular mechanisms 
that dictate maintenance of pluripotency and differentiation. The transcriptional network that ensures the 
pluripotent phenotype of Embryonic Stem Cells is at the core controlled by three Transcription Factors 
(TFs), OCT4, SOX2 and NANOG. These TFs have overlapping genomic binding sites and uphold an 
transcriptional network that favors the expression of pluripotency genes and inhibits lineage specifying 
genes1. Cell type specification on the other hand is driven by lineage specific signaling pathways and TFs 
that regulate epigenetic modifications that alter the cells’ genomic structure and transcriptional program2,3. 
This knowledge has allowed scientists to recapitulate these processes in vitro and to develop a wide range 
of protocols that can be used to create specific cell types and even fully developed and functional organs 
in vitro4. These methods not only hold great promise to replace lost tissue but has also opened new exciting 
opportunities to study development and disease5. 
The identification of pathways that initiate differentiation has also resulted in distinct culture methods that 
allow self-renew and maintenance of pluripotency. Up to almost one decade ago mouse ESCs were 
cultured in conditions that included serum components or Bone Morphogenetic Proteins (BMPs) to prevent 
differentiation. The realization that the BMP acts through the inhibition of Fibroblast Growth Factor (FGF) / 
Extracellular signal-Regulated Kinase (ERK) signaling paved the way for the development of a serum-free 
condition that includes two small molecule inhibitors (2i) to support in vitro propagation of pluripotent mouse 
ESCs6. Transcriptional and epigenetic profiling implied that serum ESC populations are naive pluripotent 
cells (hereafter referred to as “naive ESCs”) but rather heterogeneous in terms of morphology and the 
expression of core pluripotency genes. ESCs grown in 2i conditions (hereafter referred to as “ground state 
ESCs”) on the other hand are more homogeneous and are considered to “occupy a ground state in which 
the pluripotency gene regulatory circuitry is maximally operative” (reviewed by Ying, Q.-L. & Smith, A.7).  
During embryonic development lineage specification is paralleled by a steady increase in cell number. In 
between mitotic cell division proliferating cells pass consecutively through Gap1 (G1)-phase, Synthesis (S)- 
phase and G2-phase. Pluripotent cells from the ICM are characterized by extremely short Gap-phases that 
lengthen upon lineage specification during time of implantation (reviewed by Boward, B., Wu, T. & Dalton, 
S.8).  Studies on the 3D chromatin conformation revealed that cell type-specific chromatin configurations 
are detected most prominently during G1-phase and that genomic interactions that drive gene expression, 
like enhancer-promoter interactions, are taking place during G1-phase9. Similarly, in ESCs the expression 
of lineage specifiers as well as the establishment of bivalent domains at the promoters of developmental 
genes occurs specifically during G1-phase and are accompanied by chromatin reorganization and 
enhancer-promoter interactions10,11. These findings have led scientists to believe that the G1-phase serves 
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as an window of opportunity for ESCs to initiate differentiation (reviewed by Dalton, S.12). In line with this 
hypothesis several studies have indicated that mouse and human ESCs are more sensitive to 
differentiation-inducing conditions in G1-phase when compared to either S- or G2-phase and that cells 
residing in G1-phase show reduced colony forming capacities13,14.  
The G1-phase of cells both from the ICM as well as from in vitro cultured naive mouse ESCs is extremely 
short. If differentiation associated with chromatin remodeling is indeed specifically initiated during G1-phase 
this characteristic short G1-phase of ESCs could potentially serve as a barrier to prevent differentiation. 
Although elongation of G1-phase correlates well with differentiation and delaying S-phase entry has been 
shown to induce differentiation in some cases15,16 fast progression through the G1-phase is not a 
prerequisite for ESCs to maintain pluripotent. The most compelling evidence for this is in vivo diapause. 
During a period that in mice can take up to 20 days, transcriptional activity of the pluripotent cells in 
blastocyst is severely reduced and there is minimal cell division17.  In vitro diapause can be recapitulated 
by inhibiting either MYC or the mTOR pathway18,19. Although the former stalls ground state ESCs in G1-
phase it does not affect their pluripotent potential18. In line with these observations changes in the 
distribution of cells over the different phases of the cell cycle upon adaptation of ESCs to ground state 
conditions imply that the extremely short G1-phase is not an intrinsic property of ESCs but is at least in part 
the result of abundant external stimuli20,21. In spite of these differences in G1-phase, cells in both states of 
pluripotency proliferate at roughly the same pace implying that rapid proliferation is a characteristic feature 
of ESCs. What causes these cells to proliferate at such a rapid pace is still not entirely clear.  
Accumulating evidence indicates that signaling pathways and transcriptions factors of the core pluripotency 
network impact on the cell cycle. In this communication we will review how the pluripotency network impacts 
on the cell cycle, mainly focusing on OCT4, SOX2 and NANOG. Most of the studies on cell cycle regulation 
in ESCs so far have been performed however using naive ESCs. Although the number of reports on cell 
cycle control in ground state ESCs is still limited they have revealed some striking differences regarding 
the cell cycle when compared to naive ESCs. Throughout the review we will also discuss these differences 
and elaborate on their implications. Finally, we will discuss how cell cycle regulators modulate pluripotency 
and differentiation. 
Cell Cycle Control in Naive and Ground State ESCs 
Characteristic of classically cultured naive ESCs is that they lack the control mechanisms that prevent S-
phase entry. The canonical pathway that regulates G1-phase progression culminates in E2F activity that 
drives progression into S-phase. The E2F transcription factors are inhibited by the pocket protein family -
consisting of RB, P107 and P130- that in turn are inhibited by CDK/cyclin-mediated phosphorylation. Two 
families of CDK-inhibitors exist, the CIP/KIP and the INK4/ARF that can inhibit CDK/cyclin complex 
formation. One of the first observations that explained the characteristic fast ESC cell cycle was the 
absence of hypo-phosphorylated RB in naive ESCs22. Subsequent studies revealed that the RB pathway 
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is compromised in these cells and not activated in growth-inhibitory conditions (reviewed by Burdon, T.23). 
Several mechanisms might act in concert to prevent the expression of hypo-phosphorylated RB.  
One possible explanation is that in naive ESCs not only the relative amount of hypo-phosphorylated active 
RB but also the total RB protein level is low in naive ESCs compared to MEF22. Low RB levels imply that 
minimal CDK/cyclin activity suffices to induce S-phase entry and could explain rapid proliferation despite 
the low expression of CDKs in ESCs24. The expression of the pocket proteins is inhibited by the expression 
of an ESC-specific set of microRNAs25. Besides a low basal pocket protein expression level, the short G1-
phase and the inability of ESCs to arrest in G1-phase upon stress has also been attributed to precocious 
CDK/Cyclin activity resulting in hyper-phosphorylation and inactivation of RB. In contrast to somatic cells 
ESCs display a non-cyclic expression of the cyclins and early studies have indicated that fast progression 
through G1-phase in naive ESCs is mediated by constitutive CDK/cyclin expression and the absence of 
CDK-inhibitors26. Naive ESCs in general do not express these molecules and in part seem insensitive to 
ectopic expression24,27,28. It is not entirely clear why CDKi’s are not expressed in naive ESCs but the activity 
of microRNAs does contributes by repressing the expression of the CIP/KIP family of CDK-inhibitors29.  
Although this characteristic ESC-specific cell cycle is fundamentally different from the somatic cell cycle the 
underlying molecular mechanism remained elusive for more than three decades. Below we will discuss how 
certain signaling pathways and TFs of the core pluripotency network impact on the cell cycle of naive and 
ground state ESCs. 
FGF/ERK and WNT signaling 
The FGF/ERK-pathway is involved in primitive endoderm formation and germ line specification in the early 
embryo and its inhibition allows to maintain ESCs in ground state pluripotency6,30. Activation of the ERK 
pathway results in elevated activity of CDK/cyclin complexes and drives progression through G1-phase 
(reviewed by Meloche, S. & Pouysségur, J.31). We and others have recently shown that ERK-signaling 
plays a major role phosphorylation of RB and S-phase entry in naive mouse ESCs32,33. How ERK exactly 
controls phosphorylation is not entirely clear although it is likely that it involves the expression of CYCLIN 
D32,34. In ground state ESCs FGF/ERK signaling is inhibited leading to  lowered expression of Cyclin D and 
more cells in G1-phase21. The fact that inhibition of ERK signaling in naive ESCs did not fully restore the 
G1-checkpoint as present in ground state ESCs suggests that other processes contribute to the shortening 
of G1-phase in naive ESCs32. 
Besides ERK signaling, the activity of cell cycle regulators is also affected by Wnt signaling which is a 
crucial mediator of pluripotency35. Positive regulation of both Cyclin D and Cyclin E is mediated via direct 
transcriptional control by β-catenin as well as through inhibition of GSK3, which targets both cyclins for 
degradation. Wnt signaling thereby is an important positive regulator of G1- to S-phase progression in 
somatic cells (reviewed by Niehrs, C. & Acebron, S. P.36). In contract to somatic cells, active Wnt signaling 
has recently been shown to reduce the speed with which ground ESCs progress through G1-phase37. Upon 
active Wnt signaling one of the two major downstream TFs, TCF1, was recruited to the INK4/Arf tumor 
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suppressor locus and induced the expression of the CDKi’s P16 and P19. Corollary S-phase entry was 
delayed and proliferation of naive ESCs was slowed down without affecting their undifferentiated state.  
The differences in cell cycle between naive and ground state ESCs are therefor at least in part the result of 
lowered CYCLIN D and elevated CDKi expression mediated by FGF/ERK inhibition and stimulation of Wnt 
signaling, respectively. The addition of the 2i inhibitors to naive ESCs culturing in serum had however a 
less pronounced effect on the cell cycle when compared to adaptation to ground state serum-free 
conditions21. In ground state ESCs two members of the CIP/KIP family of CDKi’s, P21 and P27, are higher 
expressed when compared to naive ESCs. What causes the higher expression of these proteins is not been 
determined yet. Several ESC-specific mechanisms have shown to contribute to the shortened G1-phase in 
naive ESCs. In the next section we will consider these mechanisms and elaborate on their influence on the 
cell cycle of naive and ground state ESCs. 
OCT4/SOX2/NANOG 
Several lines of evidence have indicated that members of the pluripotency network employ multiple 
mechanisms to modulate progression through the G1-phase. Firstly, both OCT4 and SOX2 directly control 
the expression of ESC-specific microRNAs that inhibit key regulators of G1-phase progression and thereby 
contribute to the abbreviated G1-phase25,38. These microRNAs repress the expression of the pocket 
proteins as well as CDKi’s and desensitize ESCs to serum starvation39. Whether a similar mechanism is 
employed by OCT4 and SOX2 to repress the expression of the pocket proteins in ground state ESCs remain 
to be determined. However, a recent study has indicated that self-renewal of ground state ESCs has a 
higher dependence on microRNA than naive ESCs, which could be explained by the fact that ground state 
but not naive ESCs express both CDKi’s as well hypo-phosphorylated RB40.  
Secondly, CDK/Cyclin-mediated phosphorylation of RB is promoted by both SOX2 and NANOG. SOX2 can 
stimulate cell proliferation either directly as a transcriptional activator of several cyclins41–43 or as a repressor 
of P2144,45. NANOG contributes to accelerated S-phase entry through the transcriptional activation of CDK6 
and CDC25A46,47. Similar to SOX2, NANOG is able to suppress the expression of CDKi’s, NANOG binds 
upstream of the Cdkn1b gene and its expression correlates with repression of P2748. Interestingly, two 
independent OCT4-driven pathways mediate RB hyper-phosphorylation and G1-phase progression in 
naive ESCs49,50. Altogether, these results imply that the pluripotency network contributes to the 
phosphorylation of the pocket proteins and abrogation of the G1/S checkpoint. Despite the fact that OCT4, 
SOX2 and NANOG are expressed at similar levels in naive and ground state ESCs the levels of CDKi’s 
were significantly increased and no hyper-phosphorylated RB was observed during the G1-phase of ground 
state ESCs, suggesting that the core pluripotency TFs do not facilitate G1-phase progression in ground 
state ESCs. Knock down studies on these TFs combined with a more comprehensive analysis of the 
expression and phosphorylation levels of the pocket proteins in ground state ESCs are needed to determine 
whether the core pluripotency TFs do contribute to G1-phase progression in ground state ESCs.   
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MYC 
Although MYC is not considered to be part of the core pluripotency network, the MYC family of TFs has a 
well-established role in stem cell maintenance as well as cell cycle regulation (reviewed by Singh, A. & 
Dalton, S.51). MYC is a direct transcriptional regulator of both CYCLIN D and E and the MYC-mediated 
activation of CDK2/Cyclin E complexes has shown to overcome the restriction point in naive ESCs52. 
Although MYC is only lowly expressed in ground state ESCs when compared to naive ESCs no major 
differences in CYCLIN D and E expression were observed6,21. MYC however also antagonizes the 
expression of P21 and the decreased expression of MYC might therefor (next to inhibition of ERK and Wnt 
activation) contribute to the reinstatement of G1-phase control in ground state ESCs21,53. Interestingly, MYC 
is necessary for ground state ESCs to proliferate and its loss results in G1-phase arrest in ground state 
ESCs but not in naive ESCs  (18 and unpublished observations). Although MYC is well known for its role as 
a transcriptional activator of G1-cyclins the absence of hyper-phoshorylated pocket proteins in ground state 
ESCs during late G1 phase suggests that MYC-mediated S-phase entry is not CDK/cyclin-dependent. 
Previous studies have shown that MYC also mediates the expression of a microRNA cluster that targets 
the RB family protein P130 and thereby contributes positively to cell cycle progression54. It would therefor 
be interesting to assess the expression of hypo-phosphorylated pocket proteins in ground state ESCs upon 
MYC-deprivation. Such studies could provide valuable insights into the role of MYC in the ESC cell cycle. 
The fact that inhibition of MYC does not result in G1-arrest in naive ESCs confirms that not MYC but 
CDK/cyclin-driven activation of E2Fs initiates S-phase entry in naive ESCs6,32. 
 
 
Together, these results suggest that the abrogated G1-phase in naive 
ESCs is the result of high FGF/ERK activity and low Wnt signaling. Activation of Wnt signaling leads to 
transcription of the INK4/ARF locus and P16/P19-mediated elongation of G1-phase. Although inhibition of 
FGF/ERK induces the expression of P21 and P27 and reinstates the RB/E2F-mediated G1-checkpoint its 
exact molecular mechanism has not been deciphered yet. Possibly the lowered MYC expression in ground 
state compared to naive ESCs contributes to reinstatement of the G1-checkpoint. 
Figure 1. Schematic of the 
mechanistic link between 
the pluripotency and the 
cell cycle regulatory 
network. Members of the 
core pluripotency network 
and MYC promote G1-
phase progression by the 
activation of CDK/Cyclin 
complexes. In addition, 
transcriptional activation of 
microRNAs results in 
silencing of CDK-inhibitors 
and members of the pocket 
proteins that delay S-phase 
entry. 
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Effect of Cell Cycle Regulators on Pluripotency 
The discovery that somatic cells can be reprogrammed to induced pluripotent Stem (iPS) cells inspired 
many to combine this protocol with genome wide knock down or overexpression screens to identify genes 
that modulate the pluripotency network. Amongst others many cell cycle regulators were frequently 
identified to improve reprogramming55,56.  Although reprogramming is a stochastic process that is highly 
susceptible to changes in cell proliferation rates57, several studies have indicated that there are direct 
mechanistic link between certain cell cycle regulators and the pluripotency network (reviewed by White, J. 
& Dalton, S.58). In the following section we will review recent work that has uncovered a direct mechanistic 
links between the proteins that drive G1-phase progression and the pluripotency network. 
CYCLINS 
Although there is a general consensus that the main function of CYCLIN D and E is to drive progression 
through G1-phase, a recent study revealed that the cell cycle of ground state mouse ESCs does not depend 
on either one of them. Surprisingly, the combined depletion of Cyclin E1-2 and D1-3 does neither abrogate 
G1-phase progression nor successful S-phase entry in ground state ESCs59. Interestingly though, these 
cyclins elicit an important role in maintenance of pluripotency of ground state mouse ESCs through the 
stabilization of proteins of the core pluripotency network, NANOG, OCT4 and SOX2. ESCs that lack both 
Cyclin D and Cyclin E show increased expression of Cdx2 and Eomes, two transcription factors that confer 
trophectodermal differentiation59. The ability of G1-cyclins to prevent differentiation had been observed 
before, although employing a different mechanism. Cyclin D1-3 and associated CDKs contribute to 
maintenance of the undifferentiated state of ESCs by blocking the TGF-β signaling pathway that induces 
endoderm differentiation60. In addition, Cyclin D1 acts not only in partnership with CDKs but is also able to 
directly repress the expression of endoderm genes by binding and recruitment of transcriptional repressors 
to their promoters61. Together with the fact that endoderm differentiation correlates with loss of CYCLIN D1 
expression these results suggest that CYCLIN D and E are essential for upholding the core pluripotency 
network in epiblast cells of the ICM whereas trophectoderm cells and cells destined to contribute to the 
primitive endoderm lose the expression of these cyclins. In line with these results, CYCLIN E not only 
regulates G1 progression but impairs the differentiation towards extra-embryonic lineages as well62. 
Similarly, in the early blastocyst CYCLIN E colocalizes with NANOG in the epiblast whereas it is 
downregulated in trophectoderm cells that proliferate at a much slower pace8,63. The fact that CYCLIN D 
and E knock out ESCs retain the ability to differentiate to either of the three major germ layers indicating 
that G1-cyclins are critical for maintenance of pluripotency but not required for germ layer specification59. 
CDKs 
Not only the cyclins but also their catalytically active partners have been functionally linked to regulation of 
gene expression in embryonic stem cells and during lineage specification. Similar to CYCLIN D and E the 
CDKs that promote progression through the G1-phase, CDK2 and CDK4, are dispensable during embryonic 
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development until midgestation indicating that they are not required for the cell cycle of undifferentiated 
cells of the ICM. The loss of CDK1 on the other hand abrogates the first cell division upon conception and 
is considered to be the only CDK essential for undifferentiated cells to proliferate (reviewed in Malumbres, 
M. & Barbacid, M.64). The fact that CDK1 expression parallels the expression of pluripotency genes and 
that downregulation results in differentiation underpins its importance in pluripotency65. CDK1 is not only 
essential for proliferation of ICM cells but can also interact with OCT4 and thereby promote the repression 
of specifiers of the trophectoderm lineage66,67. Moreover, CDK1 is involved in a cell cycle-independent 
pathway that suppresses ERK signaling-mediated differentiation65. Together these findings suggests that 
CDK1 plays a crucial role in the early blastocyst that resembles the role of CYCLIN D and E. Besides CDK1 
an important role in maintaining pluripotency has been attributed to CDK2. Although CDK2 is dispensable 
in ICM cells CDK2-mediated phosphorylation of SOX2 enhances reprogramming MEFs68. Moreover, the 
de-repression of CDK2 prevents differentiation upon LIF withdrawal69. A recent report identified not only 
SOX2 but also NANOG and OCT4 as targets for CDK2-mediated phosphorylation59. The CDK2-mediated 
phosphorylation of these core pluripotency factors inhibits ubiquitination and subsequent degradation and 
appears to be essential for maintenance of pluripotency. CDK-mediated phosphorylation of SOX2 also 
promotes the ability of a truncated form of SOX2 to negatively regulate neuroectodermal differentiation70. 
A recent study has uncovered how CDK4 and CDK6 act in concert with D cyclins to prevent TGF-β 
signaling-driven endoderm differentiation through phosphorylation of the SMAD proteins60. On the contrary, 
the CDK4-6/CYCLIN D activity promotes neuroectoderm differentiation. Besides the core pluripotency 
factors also the activity of MYC is influenced by CDK activity. CDK8 phosphorylates and protects MYC from 
degradation. By doing so CDK8 enhances MYC target gene expression and keeps ESCs in their pluripotent 
state71. CDK9, a less well characterized member of the CDK family binds KLF4 and contributes to 
Polymerase II release at the promoters of genes belonging to the pluripotency network72. Altogether these 
results indicate that the high activity of CDKs not only results in rapid cell cycle progression in ESCs, but 
also contributes to a transcriptional program that favors maintenance of pluripotency. However, the facts 
that only CDK1 is essential in the blastocyst, that most CDKs are expressed upon differentiation and that 
CDK-mediated modulation of the pluripotency network merely inhibits the differentiation into specific 
lineages suggests that CDKs are involved in lineage specification. 
CDK-inhibitors 
Considering the role of CDKs in ESCs it seems evident that their naturally occurring counterparts have the 
opposite function. This assumption is underscored by a large body of literature that indicates that CDKi’s 
are upregulated upon differentiation (reviewed by Sage, J.73). Apart from blocking CDK/Cyclin interactions 
several CDKi’s can both repress and activate gene expression by directly interacting with TFs (reviewed by 
Abbas, T. & Dutta, A.74). The convincing evidence that CDKi’s can negative influence the pluripotency 
network comes from two studies on the role of the CIP/KIP proteins. P21 is able to repress Sox2 expression 
by directly binding to a Sox2 enhancer75 and P27 in complex with amongst others P130 is able to 
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epigenetically silence the Sox2 gene resulting in differentiation of ESCs76–78. Presumably, P21 and P27 
bind the same repressive complex and prevent the expression of target genes during G1-phase. 
Although these results imply that the expression of CDKi’s correlates with differentiation, two recent reports 
show that the picture is more complex and context dependent. Active Wnt signaling via TCF1 controls the 
expression of the Cdkn1a tumor suppressor locus, that encodes the cell cycle inhibitors P15, P16 and P19 
resulting in decreased cell proliferation while leaving the expression of pluripotency genes unchanged37. In 
a recent report we have shown that naive ground state ESCs also express active P21 and P27 resulting in 
an elongated G1 phase. Despite the higher levels of P16, P21 and P27 protein, no difference in the 
expression of Sox2 nor other core pluripotency genes was observed21,79. 
RB/E2F 
The general notion that arises from studies on the role of RB family proteins during embryonic development 
and in ESCs is that these proteins mainly play a role in differentiation. Mouse embryos lacking either Rb or 
both P107 and P130 die during peri-implantation stages and display hyper-proliferation and deregulated 
differentiation. Conform these phenotypes, in vitro cultured ESCs RB-/- cells show diminished differentiation 
potential (reviewed by Julian, L. M. & Blais, A.80). These results might be due to the fact that RB  is a 
transcriptional repressor of Sox2 and Oct4 in somatic cells 78. In mouse ESCs the pocket proteins are not 
functional and, hence, the ablation has no effect on their proliferative capacities or potential to form alkaline+ 
colonies81. On the other hand ground state ESCs do have a functional RB/E2F axis and the loss of RB, 
P107 and P130 in these cells therefore results in premature S-phase entry21. These results imply that the 
activity of pocket proteins might not only control G1-phase progression but negatively affect the pluripotency 
network in ground state ESCs as well. Despite the differential activity of these pocket proteins in naive and 
ground state ESCs these cells do not display major differences in expression of core pluripotency factors6,79. 
Furthermore, when comparing WT ESCs and ESCs lacking the pocket proteins no major differences in the 
expression of Oct4 were observed either21. It remains to be determined what causes these seemingly 
contradictory findings. Possibly one of the other proteins of the repressive complex is not available in ground 
state ESCs76,78. Whether the core pluripotency network of ground state ESCs is de-sensitized to Rb-
mediated repression or that depletion of the pocket proteins could even amplify the pluripotency network 
remains elusive. Like the pocket proteins the transcription of Sox2 gene can also be regulated by E2F 
transcription factors. Two closely related E2F proteins, E2F 3A and 3B, have opposing effects on the 
expression of Sox2. Both transcription factors bind within close distance of the Sox2 Transcription Start 
Site (TSS) but E2F3B results in lowered deposition of H3K27me3 whereas replacement of E2F3B with 
E2F3A resulted in the recruitment of a repressor complex82. How they exactly contribute to the regulation 
of the pluripotency network is however unclear. The combined deletion of all three “activator” E2Fs, E2F1-
3, did not abolish self-renewal of naive ESCs nor efficient teratoma-formation83. Only a few specific tissues 
showed impaired proliferation and increased apoptosis suggesting that they might contribute to 
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differentiation. This was confirmed by the finding that none of studied E2F family members is essential for 
cells of the ICM84. 
P53 
If cells suffer from stressful conditions progression through the cell cycle can be temporarily halted during 
G1-phase. The pathways that are responsible for G1-arrest not only act in response to stress but have also 
been shown to mediate developmentally programmed cell senescence85. An important regulator of G1-
phase progression is P53, an tumor suppressor and master regulator of stem cell quiescence86. Although 
highly expressed and active at early embryonic stages87,88 P53-/- mice are viable89 and a debate on the role 
of P53 in embryonic development is still ongoing90. A large number of studies have indicated that P53 in 
ESCs is transcriptionally inactive under normal circumstances but can mediate differentiation under 
stressful conditions by both inducing the expression of lineage specifiers and downregulation of the core 
pluripotency network (reviewed by Danilova, N.91). Upon DNA damage for example, P53 binds to the Nanog 
promoter and reduces the expression of NANOG92. Moreover, it can repress OCT4, NANOG and SOX2 by 
interfering with distal enhancer activity93. Moreover, microRNAs induced by P53 target OCT4 and SOX294,95 
and facilitate extraembryonic endoderm specification96. Recently two studies have highlighted the role of 
P53 in mesendoderm differentiation. P53 inhibits a transcriptional network that promotes pluripotency 
through the expression of long non-coding RNAs resulting in differentiation into the mesoderm and 
endoderm97. These results were confirmed by the finding that the combined deletion of P53, P63 and P73 
resulted in abrogated mesendodermal differentiation. The P53 family tweaks the collaborative WNT/TGF-
β pathway by inducing the expression of several WNT ligands98. 
In contrast to the above mentioned literature, a few studies have shown that P53 can also inhibit lineage 
commitment and contribute to an undifferentiated phenotype. Stress-induced P53 activity was shown to 
mediate the transcription of Wnt ligands that contribute to an undifferentiated phenotype99. Moreover, P53 
can elevate TGF-β signaling and concomitantly NANOG expression prevent exit of the pluripotent state by 
elevating TGF-beta signaling and accompanying NANOG expression100. 
Concluding remarks 
Early studies on ESC derived from the inner cell mass revealed an unusual short cell cycle structure that 
was subject to dramatic changes during cell fate specification23,101. The cell cycle regulated differentiation 
and accompanied chromatin remodeling led scientist to believe that the ESC-specific cell cycle structure 
and differentiation are mechanistically linked. Whether the ESC-specific transcriptional program that 
coordinates pluripotency also facilitates their highly proliferative phenotype and characteristic short G1-
phase has been subject of debate58. In this review we have summarized how G1-phase progression is 
affected by signaling pathways that dictate early embryonic development and the core pluripotency TF 
machinery plus MYC. In addition, we have tried to rationalize to what extent these biological processes 
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explain the cell cycle structure of ESCs in two distinct states of pluripotency6,102. Although ESCs in both 
states are highly proliferative, signaling pathways that ensure maintenance of pluripotency do not mediate 
uncontrolled G1-phase progression, indicating that the relative short G1-phase is not a feature of pluripotent 
ESCs21,37. In line with these observation, the presence of hypo- but not hyper-phosphorylated pocket 
proteins during G1-phase in ground state ESCs suggest that pluripotency factor-driven CDK/Cyclin activity 
is not characteristic of ground state ESCs and therefore not an intrinsic feature of pluripotent ESCs. 
Together these results imply that fast G1-phase progression and cell proliferation is not driven by 
pluripotency but is the default cell cycle, whereas cell cycle remodeling, like quiescence, is driven by either 
situations of stress or differentiation. Furthermore, we have discussed how members of the canonical G1-
restriction point modulate pluripotency and differentiation. In general, pro-proliferative members, like cyclins 
and CDKs, have a positive effect on maintenance of pluripotency. Conversely, the activity of members that 
delay G1-phase progression correlates with differentiation64. Many members that promote proliferation and 
pluripotency are however dispensable in the early ICM and rather prevent differentiation than promote 
pluripotency59,60. The latter can be explained by the fact that the initial phase of tissue development not only 
requires proper cell differentiation but sufficient cell numbers as well. 
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Summary 
Genome-wide association studies have identified a great number of non-coding risk variants for 
colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. 
Identification of allele-specific transcription factor (TF) binding is of great importance to understand 
regulatory consequences of such variants. A recently developed proteome-wide analysis of 
disease-associated SNPs (PWAS) enables identification of TF-DNA interactions in an unbiased 
fashion. Here, we perform a large-scale PWAS study to comprehensively characterize TF binding 
landscape that is associated with CRC, which identifies 731 allele-specific TF binding at 116 CRC 
risk loci. This screen identifies the A-allele of rs1800734 within the promoter region of MLH1 as 
perturbing the binding of TFAP4 and consequently increasing DCLK3 expression through a long-
range interaction, which promotes cancer malignancy through enhancing expression of the genes 
related to epithelial-to-mesenchymal transition. 
Introduction 
An individual's risk to develop colorectal cancer (CRC) is affected by a broad spectrum of genetic variants 
that abolish the functions and/or alter the expression of target genes. In CRC, two types of genetic variants 
have been extensively discussed to contribute to disease onset and progression: (1) protein-coding 
mutations; (2) non-coding variants in particular in DNA regulatory elements (DREs). To date, the majority 
of studies have focused on protein-coding mutations. Key coding mutations, such as APC/CTNNB1, 
KRAS/BRAF, PIK3CA, TP53, and SMAD4, have been intensively characterized1. However, even though a 
great number of non-coding risk variants for CRC have been identified in genome-wide association studies 
(GWAS)2–9, their molecular functions have rarely been determined. 
Functional genetic variants in distal DREs may alter transcription networks in several ways such as by 
affecting TF binding. SNPs within TF binding sites may affect the local chromatin accessibility10–12 and/or 
alter the expression of gene targets through mediating different chromatin interactions13–15. Therefore, 
identification of variant-specific TF interactors is of great importance to understand regulatory 
consequences of the variants. However, DNA oriented methods, such as DNase I sequencing (DNase I-
seq)16, systematic evolution of ligands by exponential enrichment sequencing (SELEX-seq)17 and 
chromatin immunoprecipitation with massively parallel DNA sequencing (ChIP-seq)18, are biased by DNA 
motif knowledge or limited by the availability of antibodies, resulting in a biased identification of TF binding 
dynamics at disease associated loci. A recently developed proteome-wide analysis of disease-associated 
SNPs (PWAS) enables to identify DNA-TF interactions in an unbiased fashion19. A similar approach has 
been used to characterize a protein-DNA interaction map for ultra-conserved elements20. Therefore, we 
performed a large-scale PWAS studies to comprehensively understand TF binding landscape related to 
CRC. 
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As the outcome from our PWAS screen, we further investigated the functions of a SNP located in the 
promoter region of MLH1 gene (MLH1-93G>A or rs1800734), which has been associated with the risk of 
several cancer types including CRC9,21,22, endometrial cancer23, glioblastoma24 and lung cancer25. Here, 
we identified a molecular function of this SNP in promoting cancer malignancy through a novel gene target 
named DCLK3. 
Results 
PWAS identified TF occupancy switching at the 116 loci 
We selected 116 SNPs associated with CRC risk2–9 for PWAS analysis including (1) typed and imputed  
GWAS significant SNPs (for imputed SNPs, LD r2≥0.2) from 8q24.21 (MYC-335), 15q13.3 (GREM1) and 
18q21.1 (SMAD7), (2) SNPs with functional evidence rs16969681/15q13.326, rs58920878/18q21.127, 
rs16888589/8q23.328 and rs4444235/14q22.229, (3) 3 SNPs from 3p22.2 (MLH1 region)9, and (4) GWAS 
significant SNPs in DNase I-seq peaks in minimal one of 15 fetal large intestine tissues and 12 CRC cell 
lines (Supplementary Data 1). The PWAS analysis identified 731 TF binding alterations between reference 
(Ref) and alternate (Alt) alleles (P<0.01, A/B significance test) (Supplementary Data 2). Compared to 
proteome data, TF-DNA interactome data showed a clear enrichment for TFs (Supplementary Fig. 1a), and 
the altered binding events mediated by known TFs (Supplementary Data 3) showed stronger allele 
preference than other interactions (P= 4.4x10-6, Mann-Whitney U test) (Supplementary Fig. 1b). Overlay of 
the pull-downs showed a consistent allele preference between 2 replicate experiments (Supplementary Fig. 
1c). Many of the 731 TFs showed >8 fold affinity to one of the alleles at these loci (Fig. 1a), e.g. TFAP4 at 
rs1800734 and RUNX1/RUNX2/CBFB at rs1741640. As expected, top pathways associated with the 731 
TFs included key CRC drivers such as WNT and TGF-β pathways (Fig. 1b).  
It is well-known that DNase I hypersensitive sites coincide with regulatory elements and are the hotspots 
for TF binding16. To better predict in vivo TF binding, it is necessary to consider the hypersensitivity of tested 
regions. Therefore, we ranked all the SNP-TF interactions based on PWAS fold change (Ref/Alt allele) and 
DNase I hypersensitivity (DHS) of the SNP loci. A total of 27 significant allele-specific SNP-TF binding 
events were considered to be important (Fig. 1c and Supplementary Table 1). Many selected TF-SNP 
interactions (Fig. 1d and Supplementary Fig. 1d) were validated using ChIP-seq data (Supplementary Fig. 
1e). Based on this selection, the top candidate SNP is rs1800734 (MLH1 -93 G>A) in the 5'-UTR region of 
MLH1 gene. Therefore, we decided to focus on this SNP. 
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PWAS identified specific interactors of rs1800734 
Our PWAS screen identified TFAP4 as an allele-specific interactor with an almost 16-fold higher affinity for 
G-allele, while ELF1 showed higher affinity for the A-allele of rs1800734 in LoVo cells (Fig. 1d). The A-
allele abolishes TFAP4 binding due to a point mutation at the last position of the E-box (Fig. 2a), which 
simultaneously creates an ETS family binding motif (Supplementary Fig. 2a). We corroborated and 
extended this finding by label-free based DNA pull-down with SNU175 and COLO320 extracts (Fig. 2b & 
supplementary Fig. 2b). Notably, other bHLH and ETS family members also displayed allele-specific 
binding, including MYC and ELF2 (Supplementary Fig. 2b/c), indicating that these TFs can compete with 
TFAP4 and ELF1 at this locus. Using ChIP-seq as an orthogonal technique, we validated TFAP4 and ELF1 
binding at the rs1800734 in the SNU175 and COLO320, cell lines heterozygous for this locus. Consistent 
with PWAS, TFAP4 ChIP-seq showed a dominant preference for G-allele binding in the two cell lines (Fig. 
2c). ELF1 did not show significant allele binding preference (Supplementary Fig. 2d), which may be due to 
the competitive binding interference by other ETS proteins. 
DCLK3 is a novel target of rs1800734 
Given the position of the SNP in the promoter of MLH1, we further investigated whether predisposition of 
rs1800734 in CRC is due to DNA methylation of MLH1 promoter as proposed9,30. We tested hypersensitivity 
and transcription of G- and A-allele in the two heterozygous cell lines, which showed the two alleles are 
equally accessible and transcribed (Fig. 2d). The neighbouring gene EPM2AIP1, also reported to be 
regulated by rs180073431, was similarly unaffected by rs1800734 (Fig. 2d). Hence we conclude that 
rs1800734 does not result in allele-specific epigenetic silencing of either MLH1 or EPM2AIP1 in these cell 
lines. We sought to confirm our observation in the Systems Biology of Colorectal Cancer (SYSCOL) cohort 
of paired healthy and tumor tissues (healthy: n=288, tumor: n =289). A strong eQTL between rs1800734 
and MLH1 was observed in the healthy tissues (P=0.001, linear regression model) but the A-allele was 
associated with increased MLH1 expression. This eQTL was lost in the tumors and remained only a weak 
association in microsatellite stable (MSS) tumors (P=0.025, n=236, linear regression model) 
(Supplementary Fig. 3a). Intriguingly, we identified a correlation between rs1800734 and DCLK3 
Fig. 1 PWAS screen systematically identified allele-specific TF binding at the selected CRC risk 
loci. (a) Allele-specific binding of the 731 candidate TFs at the 116 CRC risk loci. Chromatin 
environment of the 116 SNPs was described by DNase I hypersensitivity (DHS) of these loci in the 15 
fetal large intestine tissues and 12 CRC cell lines, and histone modifications (H3K4me3, H3K4me1, 
and H3K27ac) within ±1 kb regions around these loci in the LoVo and HCT116 cell lines. The TFs with 
P-value<10-30 and absolute Log2(fold change)>3 was listed in the bubble plot. Bubble size represents -
Log10(P-values) of the interactors in the pull-down screen (n=2 pull-downs per SNP, P-values: A/B 
significance test). (b) Pathway annotation of the 731 TFs (HR: Gonadotropin releasing hormone 
receptor pathway, WNT/PDGF/CCKR/TGF-β: Wnt/PDGF/Cholecystokinin/TGF-beta signaling 
pathways). (c) TF-SNP interactions ranked by fold changes in the PWAS screen and DHS at the SNP 
loci. Bubble size indicates the -Log10(P-values) of the TF-SNP interactions (n=2 pull-downs per SNP, 
red and blue bubbles: P-value<0.05, Z-test). (d) The top 3 candidate TF-SNP interactions (n=2 pull-
downs per SNP, red and blue dots: P-values<0.01, A/B significance test). 
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expression in the healthy (P=0.029, linear regression model) and tumor (P=0.031, linear regression model) 
samples, and this association was highly significant in the MSS patients (P=0.004, linear regression model) 
(Fig. 2e), indicating this locus may act as a distal enhancer and regulate DCLK3. 
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The A-allele positively regulates transcription of DCLK3  
To establish the functional relation between rs1800734 and DCLK3 expression, two isogenic cell lines 
homozygous for G- or A-allele were generated from COLO320 using CRISPR-CAS9 technique (Fig. 3a). 
Successful targeting of rs1800734 was confirmed by Sanger sequencing (Fig. 3b). No other mutation was 
observed in the surrounding region. ChIP-qPCR confirmed higher TFAP4 binding to the G-allele 
(Supplementary Fig. 3b), and the level of MLH1 and EPM2AIP1 transcription was identical in the three 
isogenic lines (Supplementary Fig. 3c). Importantly, the eQTL association between rs1800734 and DCLK3 
expression was replicated, and a 5-fold difference in DCLK3 expression was observed between G- and A-
homozygotes (Fig. 3c). By sequencing the inter-exonic RT-qPCR products of DCLK3, we confirmed the 
transcription of DCLK3 in these cell lines (Supplementary Fig. 3d). 
rs1800734 regulates DCLK3 through long-range interactions 
A capture HiC study has suggested that rs3806624 in the promoter of EOMES affects AZI2, a gene 640 
kbp down-stream to this SNP, through a long-range chromatin interaction14. A similar constellation may 
apply to rs1800734. Therefore, 4C-seq was employed to search for long-range interactions between 
rs1800734 and other potential targets in the three isogenic cell lines. Using rs1800734 as a view point, a 
significantly enhanced interaction was observed in A-homozygote with DCLK3 region (Fig. 3d). Increased 
interactions were found in the promoter and 3'-UTR region of DCLK3 in two independent experiments (Fig. 
3e), and additionally the 3'-UTR interaction appeared to increase chromatin accessibility (Fig. 3f). In 
conclusion, the A-allele of rs1800734 increases the DCLK3 transcription through increased chromatin 
interaction and enhanced chromatin accessibility. 
 
Fig. 2 Identification of allele-specific interactors for rs1800734 and its potential gene targets. (a) 
Motif analysis interpreted that A-allele of the loci perturbs E-box motif. (b) The specific binding of TFAP4 
(P1=2.0×10-6, P2=3.1×10-5, P3=7.8×10-5, Student’s t-test) and ELF1 (P1=2.1×10-4, P2=0.011, 
P3=6.9×10-4, Student’s t-test) on G- and A-allele was observed in the three different cell lines (Data are 
represented as mean and error bars indicate s.d., n=3 pull-downs per SNP). ZFP62 binding on A-allele, 
as shown in Fig. 1d, was not consistent in all the three cell lines, and was hence not considered as the 
general TF regulator at this locus. (c) This allele-specific binding was validated by ChIP-seq of TFAP4; 
This SNP did not change (d) local chromatin accessibility and the expression of two cis-regulated genes 
(MLH1 and EPM2AIP1) (G (G-allele) and A (A-allele) of rs1800734, wt (wild-type allele) and del 
(deletion allele) of rs35149869, P-values: Fisher's exact test). (e) eQTL analysis revealed a novel gene 
targets DCLK3 of this SNP (P-values were calculated in FastQTL software based on linear regression 
model). 
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DCLK3 is a potential oncogenic and tumor progressive factor 
DCLK3 is one of three doublecortin-like kinases (DCLK1, DCLK2, and DCLK3). In this family, DCLK1 has 
been shown to be a cancer stem cell marker in intestinal tumors32. The molecular function of the DCLK3 
has not been characterized in depth. We therefore performed gene set enrichment analysis (GSEA) to 
identify DCLK3 associated gene sets in the SYSCOL RNA-seq cohort. Interestingly, we found that 
epithelial-to-mesenchymal transition (EMT) related genes were highly correlated to the expression of 
DCLK3 in the healthy tissues (normalized enrichment score/NES=2.50), which was enhanced in the tumor 
samples (NES=3.10) (Fig. 4a and Supplementary Table 2). Using a cutoff of NES at 2.00, we also identified 
gene sets that are preferentially enriched in the healthy versus tumor tissues (Supplementary Table 2), e.g. 
"MYC targets" and "G2/M checkpoint" gene sets were enriched in the healthy tissue, whereas 
"Angiogenensis" and "TNFA signaling via NF-ĸB" gene sets were enriched in the tumor tissues (Fig. 4a). 
As expected, common EMT markers, such as CALD1, FN1, SNAI1, SNAI2, TWIST1, VIM, ZEB1 and ZEB2, 
were highly significantly co-expressed with DCLK3 in the tumors (Fig. 4a), indicating that DCLK3 is an EMT 
regulator. Furthermore, we observed elevated DCLK3 expression in the tumor compared to healthy tissues 
(P=2.2×10-16, Mann-Whitney U test) (Fig. 4b), but no difference between the MSI and MSS tumors (Fig. 
4b). Interestingly, this elevation appeared to be correlated with the CRC progression: DCLK3 expression 
was at a comparable level in the healthy and adenoma tissues, and increased ~2-fold in the stage I tumors 
and remained at this level during tumor malignancy (P=2.2×10-16, Kruskal-Wallis test) (Fig. 4b). Therefore, 
DCLK3 may promote EMT events and consequently drive tumor malignancy. 
 
Fig. 3 Molecular regulatory mechanisms of rs1800734 on DCLK3. (a) Isogenic cell lines possessing 
homozygous mutations (G/G and A/A) at rs1800734 were generated and (b) confirmed, and (c) the 
expression of DCLK3 was elevated in the A/A cell line (Data are represented as mean and error bars 
indicate s.d., n=4 biological replicates per cell line, P-values: Student’s t-test). (d) 4C-seq identified 
chromatin interactions between rs1800734 and the DCLK3 region. (e) The A/A cell line showed stronger 
chromatin interaction than other cell lines (Data are represented as mean and error bars indicate s.d., 
n=2 biological replicates per cell line). (f) The enhanced chromatin interaction results in increased 
chromatin accessibility at 3'-UTR region of DCLK3 in the A/A line. 
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Discussion 
Our study generated the first TF-SNP interaction map at presumed disease relevant loci of CRC and 
determined TF binding occupancy at the 116 upmost relevant CRC risk loci. Together with GWAS and 
epigenetic profiling data, our PWAS screens provide a comprehensive TF binding landscape of these loci 
and yielded candidate interactions for further functional investigations (Fig. 1a/c/d and Supplementary Fig. 
1d/e). As an alternative tool to investigate allele-specific TF binding events, the PWAS approach shows 
several advantages over the DNA-centric methods. In contrast to ChIP-seq technique, PWAS based 
identification is a hypothesis-free approach which does not require any knowledge on the possible binding 
TFs at risk loci. Also, application of PWAS approach is not limited by the availability of high quality ChIP 
grade antibodies. Even though large ChIP-seq datasets have been generated18,33, these data nevertheless 
cover only a small proportion of the entire repertoire of TFs. Other DNA-centric methods, such as DNase I-
seq or ATAC-seq, are only capable of identifying DNA motifs present at risk loci, which makes it difficult to 
predict actual binding TF(s) from a family sharing similar motifs in a specific cell type. The outcome of 
PWAS is a reflection of TF abundance, TF ability to bind to the sequence (affinity) as well as synergistic 
and antagonist effects due to binding of other TFs to adjacent or overlapping sequences. Therefore, actual 
binding TFs in a given cell type can be predicted using PWAS method. In addition, PWAS approach also 
help to identify binding TFs at the loci only partially matching consensus motif sequences, and therefore 
cannot be predicted by motif prediction based methods. 
Based on the PWAS screen, we investigated in great depths for a well-known CRC associated SNP: MLH1 
-93G>A or rs1800734. It has been postulated that A-allele (risk allele) of the rs1800734 recruits repressive 
TFs which subsequently results in promoter methylation of MLH1 gene9,30, supported by an association 
between the A-allele of the rs1800734 and promoter methylation34 or decreased expression of MLH135,36. 
However, Suter and colleagues showed contradictory results that A-allele of this SNP is associated with 
lower promoter methylation and higher transcription of MLH137. Our results suggested that TFAP4 
preferentially binds to T-allele of the rs1800734 but does not change promoter accessibility and transcription 
Fig. 4 Identification of DCLK3 associated gene sets and clinical parameters in the SYSCOL RNA-
seq cohort. (a) GSEA analysis revealed DCLK3 correlated cancer hallmark gene sets. EMT and 
oxidative phosphorylation associated gene sets were highly significantly associated with the DCLK3 
expression in both healthy and tumor tissues. Also, some DCLK3 associated gene sets showed healthy 
or tumor tissue specificity (P-values were calculated in GSEA based on Pearson correlation). The 
expression of key EMT markers showed good correlation with the DCLK3 expression. (b) The DCLK3 
expression was preferentially elevated in the tumors and especially the malignant tissues. However, we 
did not observe a clear difference between MSI and MSS tumors (P-values: Mann-whitney U test/MW-
test and Kruskal-Wallis test/KW-test). (c) A proposed model describing how rs1800734 modifies the risk 
of CRC malignancy. TFAP4 and ETS family members specifically bind to the protective G- or risk A-
allele, respectively. The rs1800734-ETS interaction increases the enhancer activity of the rs1800734 
locus and enhances the expression of DCLK3 through an increased chromatin interaction. Cancer cells 
with the elevated DCLK3 expression undergo EMT and therefore metastasize to distal sites. 
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of MLH1. Analysis of the SYSCOL cohort strengthened the findings in the cell lines (Supplementary Fig. 
3a) and identified a new gene target DCLK3 in the MSS patients (Fig. 2e). Furthermore, CRISPR-CAS9 
facilitated to generate fully comparable isogenic lines carrying G- or A-point mutation at rs1800734 locus. 
Therefore, mild changes in chromatin interaction, accessibility and consequently gene expression can be 
monitored by different genomic techniques. It has been shown that some functional SNPs in enhancer 
regions result in subtle changes in expression of their target genes, e.g. the G-allele of rs356168 increased 
SNCA expression by 1.06 times in neurons and 1.18 times in neuron precursors38. Hence, accurate genome 
editing is required to distinguish these subtle changes. Using this model system, an increased DCLK3 
transcription was detected in the A/A homozygous line (Fig. 3c), which is due to increased chromatin 
interaction between the two locus and consequently elevated chromatin accessibility in the DCLK3 region 
(Fig. 3d/e/f). These data confirmed that rs1800734, even though locates in the promoter region of MLH1, 
serves as a distal enhancer for the DCLK3 gene. Notably, our findings are based on the genetic background 
of MSS tumors, which is likely responsible for the contradiction between our data and some of the literature. 
Moreover, DCLK3 has been shown to be associated with EMT process in this study (Fig. 4a). Although the 
full molecular mechanism of DCLK3 in regulating EMT has not been characterized, this protein has been 
shown to directly interact with CDK539, and the latter promotes breast cancer metastasis through regulating 
TGF-β1 induced EMT40. Alternatively, CDK5 also prevents phosphorylation and degradation of a EMT 
regulator CALD141 and hence promotes the EMT process42. Furthermore, DCLK3 may perform a similar 
function as another doublecortin-like kinase DCLK1, since it possesses the similar protein kinase domain 
and one of the two doublecortin domains43 as DCLK1. In intestinal tumors, DCLK1 often co-expresses with 
LGR5 at crypt base, and DCLK1+LGR5+ stem cells are able to continuously produce tumor progeny under 
the APC+/- mice32. A further study showed that DCLK1+ cells are long-lived and quiescent population,  that 
is only activated and display carcinogenesis properties upon oncogenic mutation and tissue injury44. 
In summary, we conclude that ETS family TFs preferentially bind to the A-allele of rs1800734 and increase 
chromatin interaction between the rs1800734 locus and the DCLK3 region. This enhanced chromatin 
interaction in turn increases the expression of DCLK3. Consequently, the risk of tumor metastasis is 
increased due to increased EMT feature of cancer cells (Fig. 4c). In addition, our study systematically 
identified changes in TF binding at regulatory CRC risk loci, which provide candidates for functional follow-
up. 
Methods 
Cell culture and extraction of nuclear soluble fraction 
Human colorectal cancer cell lines were cultured in DMEM or RPMI medium supplemented with 10% fetal 
bovine, 100 U/ml penicillin and 100 µg/ml streptomycin. LoVo and SNU175 cell lines were purchased from 
American Type Culture Collection (ATCC) and Korean Cell Line Bank (KCLB), respectively. COLO320 cell 
line was a generous gift of Dr. Riccardo Fodde (Erasmus Medical Center Rotterdam, The Netherlands), 
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which is originally from ATCC. The authenticity of the cell lines were confirmed using microsatellite STR 
assay by the suppliers of the cell lines. Mycoplasma infection was routinely tested in house to ensure that 
all the cell lines used for this study were free of mycoplasma contamination. Nuclear soluble fraction of 
LoVo, SNU175 and COLO320 was performed using a published protocol45. Protein concentration of the 
obtained nuclear extract was quantified using Branford assay. Each of the 3 mg extract (12 individual DNA 
pull-downs) was aliquoted, snap-frozen in liquid nitrogen and stored at -80oC. 
High throughput DNA pull-down 
High throughput DNA pull-down experiments was performed on 96-well filter plate format using our 
published method46 with minor modifications. To synthesize biotinylated dsDNA oligo, we attached a non-
genomic 15 bp sequence at the 3' end of the anti-sense strands. Subsequently, a reverse complement 
biotinylated primer was used to extend single-stranded DNA (ssDNA) templates into dsDNA oligos. For 
each synthesis, 150 pmol of the biotinylated primer and 200 pmol template were subjected to a PCR 
reaction using Herculase II Fusion Enzyme kit under the following conditions: 95oC for 3 min; thermocycling 
(n=20) at 95oC for 1 min, 45oC for 1 min and 72oC for 1 min; 72oC for 3 min; infinite hold at 12oC. Briefly, 
high throughput DNA pull-down was performed using a Multiscreen filter plate with 1.2 μm pores (Millipore, 
MSBVN1210). The biotinylated dsDNA oligos were immobilized on 20 µl of high-performance streptavidin 
sepharose (GE Healthcare, 17511301). Two-hundred fifty µg nuclear extracts and 15 µg of competitors (5 
µg of poly(deoxyinosinic-deoxycytidylic) acid sodium salt (Sigma-Aldrich, P4929), poly(deoxyadenylic-
thymidylic) acid sodium salt (Sigma-Aldrich, P0883) and Bakers yeast RNA (Sigma-Aldrich, R6750)) were 
added and incubated with immobilized oligos for 1.5 h at 4oC on a plate shaker for each of the pull-down 
experiments. The components of the competitors were sonicated into ~300 bp fragments prior to use. The 
proteins unbound to DNA oligos were washed off using different washing buffers and the bound TFs were 
on-bead digested overnight using trypsin/lysC. The pull-down duplicates underwent dimethyl label 
swapping and measured by nLC-MS/MS in a 2h gradient. 
Nuclear extract proteome 
Deep proteome profile was generated from the nuclear extracts used for the pull-down experiments. An 
absolute quantification strategy was taken following a published method46. In brief, 3.3 µg of universal 
protein standard 2 (UPS2, Sigma-Aldrich) and 10 µg of the nuclear extracts were mixed and subjected to 
a filter-aided sample preparation (FASP) digestion. In parallel, 30 µg of the nuclear extracts were also 
digested using the FASP protocol and subsequently separated into 6 fractions using strong anion 
exchange. The UPS2 sample and the fractions was purified on C18 stage-tips and profiled by nLC-MS/MS 
in a 4h gradient. 
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DNase I-seq 
DNase I library of the LoVo cell line was constructed following a reported protocol with some minor 
modifications47. In short, 5×106 nuclei were isolated using a buffer (15 mM Tris-HCl (pH=8.0), 15 mM NaCl, 
60 mM KCl, 1 mM EDTA (pH=8.0), 0.5 mM EGTA (pH=8.0) and 0.5 mM Spermidine) supplemented with 
0.05% IGEPAL CA-630 detergent. Subsequently, the isolated nuclei were digested with 80 U DNase I 
(Sigma-Aldrich, D4527) for 3 min and the digestion was quenched by a stop buffer (50 mM Tris-HCl 
(pH=8.0), 100 mM NaCl, 0.1% SDS, 100 mM EDTA (pH=8.0), 1 mM Spermidine and 0.3 mM Spermine). A 
9% Sucrose gradient was applied to fractionate the samples for 24 h at 25,000 rpm at 16oC, and the 
fractions with <1 kb fragments were further purified and prepared according to the Illumina library 
preparation protocol. 
DNase I library of other cell lines were prepared using a published protocol18 as described below. The cell 
lines were harvested under the confluence of 60% and washed with PBS. Nuclei were isolated with RSB 
lysis buffer (10 mM Tris-Cl, pH=7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630) at 4°C for 10 min. 
Then the nuclei were treated with 0.12 unit of DNase I (Roche) in the provided buffer at 37 °C for 15 min 
before being quenched by 50 mM of EDTA. Following RNase A (Sigma) treatment at 37 °C for 15 min, 
proteinase K (NEB) was added for an additional hour at 56°C. DNA was extracted using 
Phenol:Chloroform:Isoamyl-Alcohol. Agarose Gel (2%) electrophoresis was applied to separate the 
released fragments (~100 bp) that were purified (Qiagen, MinElute Gel Extraction Kit), followed by 
Illumina TruSeq library preparation and Sequencing (HiSeq2000). 
ChIP-seq and ChIP-qPCR 
ChIP assays were performed following a standard protocol. Cell lines were cross-linked by a final 
concentration of 1% paraformaldehyde for 10 min and subsequently cross-linking reaction was quenched 
using 1.5 M glycine. The harvested cell lines were then lysed and sonicated to obtain ~300 bp chromatin 
using Bioruptor Plus sonication device (Diagenode). The sonicated chromatin was pre-cleared by Protein 
A/G magetic beads (ThermoFisher Scientific, 88802) and then incubated together with antibody 
conjuncated beads overnight at 4oC. Antibodies against H3K27ac (Diagenode, C15410196, 1 µg per ChIP 
assay), TFAP4 (Santa Cruz Biotechnology, sc-18593X, 6 µg per ChIP assay) and ELF1 (Santa Cruz 
Biotechnology, sc-631X, 4 µg per ChIP assay) were used in our ChIP experiments. Posterior to the 
incubation, captured chromatin was washed, eluted and de-crosslinked. Resulted DNA fragments were 
purified and prepared according to Illumina library preparation (H3K27ac ChIP) or KAPA Hyper Prep 
(TFAP4 and ELF1 ChIP) protocols prior to sequecning, or directly quantified using SYBR Green based 
qPCR assays (Supplementary Table 3). 
ATAC-seq 
ATAC libraries of the SNU175 and COLO320 cell lines were prepared by a documented protocol48 with 
some modifications. In brief, nuclei were isolated using a lysis buffer consisting of 10 mM Tris-HCl (pH=7.5), 
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10 mM NaCl, 3 mM MgCl2 and 0.1% IGEPAL CA-630 detergent and then tagmentated49 using 2 µl of Tn5 
transposase and 12.5 ul 2X TD buffer (Illumina, Nextera DNA Library Preparation Kit). The resulted DNA 
fragments underwent 2 sequential 9-cycle PCR amplification, and in between two PCR reactions the 
libraries were selected for <600 bp fragments using SPRI beads. The final PCR products were purified and 
quantified by KAPA Library Quantification Kits prior to sequencing. 
Targeted RNA-seq and RT-qPCR 
Total RNA was isolated from the SNU175 and COLO320 cell lines using a TRIzol reagent (ThermoFisher 
Scientific, 15596018) based method. The yielded RNA was treated using DNase and then reversely 
transcribed into cDNA using random hexamers  (ThermoFisher Scientific, SO142). The cDNA was amplified 
using targeted primers and followed by standard KAPA Hyper Prep protocols, or directly quantified using 
SYBR Green based qPCR assays (Supplementary Table 3). 
CRISPR-CAS9 based SNP editing 
CRISPR-CAS9 based SNP editing were performed according to a previously reported method50. Guide 
RNAs (sgRNAs) were designed using an online tool (http://crispr.mit.edu/) and double-nicking strategy was 
taken to reduce undesirable off-target mutagenesis. The sgRNAs were then cloned into a U6-driven plasmid 
containing a GFP marker and the D10A mutant Cas9 nickase (Addgene, pSpCas9n(BB)-2A-GFP, 
Plasmid#48140). The plasmid was then transformed into the DH5α competent E.coli strain and the products 
were purified for transfection. Subsequently, 2 sgRNAs (400 ng per each) and an 199 bp single-stranded 
oligonucleotides (10 pmol ssODNs, possessing G or A point mutations at the rs1800734 locus) were co-
transfected into COLO320 cell lines following a standard lipofectamine LTX Reagent protocol 
(ThermoFisher Scientific, 15338100). Fluorescence-activated cell sorting (FACS) was used to sort 192 
GFP-positive cells per cell line (G or A point mutations) into 96-well plates in 36 h after the transfection. In 
parallel, a wild-type cell line was treated in the same manner by without using sgRNAs, and this mocked 
cell line was then sorted by FACS and served as the control. The desirable genotype at the rs1800734 was 
confirmed by Sanger sequencing. The oligos (sgRNAs and ssODNs) used in these experiments were listed 
in Supplementary Table 3. 
SNP genotyping 
SNP genotyping was performed by a standard Sanger sequencing based method. The regions containing 
mutations were PCR amplified into ~500 bp fragments using specific primers (Supplementary Table 3) and 
the PCR products were purified using 1.5% agarose gel. A mixture of 10 ng purified PCR products and 6 
pmol primers was used for Sanger sequencing and the data were analyzed using CodonCode Aligner 
(V.5.0.2). 
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4C-seq 
4C experiments were carried out using a published protocol51 with some modifications. For each assay, 
1×107 cells were cross-linked and quenched as in ChIP assays. Nuclei were isolated in a 50 ml of lysis 
buffer (10 mM Tris-HCl (pH=7.5), 10 mM NaCl, 0.2% IGEPAL CA-630 detergent and 1X protease 
inhibitors). Subsequently, the nuclei were digested with 240 U NlaIII enzyme (NEW ENGLAND BioLabs 
Inc., R0215L) followed by an overnight in-nuclei ligation with 4,000 U T4 ligase (NEW ENGLAND BioLabs 
Inc., M0202M) at 16oC. The ligated DNA was de-crosslinked, purified, digested with 90 U CviQI enzyme 
(NEW ENGLAND BioLabs Inc., R0639S) and circularized by 5,000 U T4 ligase. The circularized DNA (16 
× 300 ng) was amplified with bait-specific inverse primers (Supplementary Table 3), pooled and purified, 
followed by KAPA Hyper Prep protocols. 
Proteomics data processing 
Recorded MS files were analyzed by MaxQuant software (version 1.3.5.7)52 using standard settings for 
dimethyl or label-free quantification analysis. All the files were searched against UniProtKB/Swiss-Prot 
human database (generated from version 06-2012). Batch effects of the pull-down data were removed 
using "Combat" algorithm53. In dimethyl analysis, some proteins were consistently quantified in the pull-
downs of only one-allele (Ref- or Alt-allele) in two replicate experiments, and the protein ratios can therefore 
not be obtained from MaxQuant output. Therefore, we imputed the missing value in these pull-down using 
"Replace missing values from normal distribution" option in Perseus software (version 1.3.9.18)54, which 
allows to further calculate protein ratios and perform down-stream analysis. TF interactors for each of the 
pull-down were identified using 'Significance B' function in Perseus software. 
DNase I-seq ChIP-seq ATAC-seq data processing 
Read mapping was performed using BWA-ALN (DNase I-seq and ChIP-seq) and BWA-MEM (ATAC-seq)55 
against the hg19 reference human genome. PCR-duplicates were removed for further data analysis. Peak 
calling was carried out by MASC256 with default settings, except H3K27ac peaks were called using "broad" 
option. Peaks were called at a q-value cutoff of 0.01. Overlapping peaks were merged for each of the 
different experiments before further analysis. Integrative Genomics Viewer (IGV)57 was used to detect bi-
allelic differential binding and hypersensitivity. 
Targeted RNA-seq and RNA-seq data processing 
Targeted RNA-seq data were mapped to the hg19 reference human genome using BWA-MEM55. IGV57 
was used to visualize the targeted RNA-seq data and detect bi-allelic differential expression. The SYSCOL 
RNA-seq cohort was mapped to the human reference genome sequence (GRCh37 autosomes + X + Y + 
M) using GEM mapper58. The reads with mapping quality <150 were excluded for further analysis. The 
genes were annotated using Ensemble 75. The reads of the genes were counted by "HTSeq" framework59 
and normalized using "DESeq" package60. 
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Calculate significance of the TF-SNP interactions 
Importance of the TF-SNP interaction in our screen study was considered by combining DNase I 
hypersensitivity of the SNPs (read counts at the SNP position in 15 fetal large intestine tissues and 12 CRC 
cell lines) and the interaction strength (Log2(fold change) of a TF between Ref and Alt allele pull-down). 
The detailed P-value calculation was performed using z-test based on following steps: (1) Calculate 
average DNase I hypersensitivity (average DNase I-seq reads) of all the 116 loci in the DNase I-seq data 
from 15 fetal large intestine tissues and 12 CRC cell lines, and then z-score transform the hypersensitivity 
data of these loci; (2) Calculate absolute Log2(fold change) of every TF-SNP interaction between Ref and 
Alt alleles, and then z-score transform the absolute Log2(fold change) of all the interactions; (3) Average 
the z-scores of DNase I hypersensitivity and absolute Log2(fold change), and convert the average z-scores 
into P-values based on normal statistical distribution. 
eQTL analysis 
The eQTL analysis was performed as described in a previous publication61. Germline genotypes of these 
patients were genotyped on the Illumina 2.5M Exome v1.0 and imputed to 1000 genomes phase 3 release 
using IMPUTE2. For cis-eQTL analysis, we normalized gene quantification separately for healthy and 
tumour samples. Technical covariates were discovered using the PEER program62 and 20 PEER factors 
were used in normalization. The cis region was defined as ± 1 Mb from the transcription start site for each 
gene. The associations between genotypes and gene quantification were obtained using the FastQTL 
software63. 
4C-seq data processing 
A reduced genome was generated by extracting the sequences flanking the NlaIII restriction sites (30 bp 
on each strand from the NlaIII restriction sites to downstream) using the hg19 reference human genome in 
order to improve the mappability of our 4C-seq data. Subsequently, the mappability of the reduced 
sequences from each strand was evaluated and the uniquely mappable NlaIII restriction sites were kept for 
downstream analysis. 
The reads from each library were parsed based on the bait-specific primer sequence and mapped to the 
reduced hg19 genome using BWA-ALN with the default parameters. A Bioconductor package "r3Cseq"64 
with 2.5 kb sliding window was used to determine significant interactions and calculate interaction 
difference. 
Pathway annotation and Gene set enrichment analysis 
TFs binding differentially to the 116 loci were annotated to PANTHER pathways using PANTHER 
Classification System65. 
GSEA analysis66 was applied to identify the gene sets correlated to DCLK3 expression. The search was 
performed against hallmark gene sets in Molecular Signatures Database (MSigDB, v5.1)67. 
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Data availability  
Raw and processed LC-MS/MS data and sequencing data are available at ProteomeXchange 
(http://www.ebi.ac.uk/pride/) and Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under the 
accession numbers PXD004435 and GSE83968, respectively. The publically available data used in this 
study were downloaded from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) using the 
following accession numbers: (1) H3K4me1 and H3K4me3 ChIP-seq: GSM1240111, GSM945304, 
GSM1208810, GSM1208811; (2) DNase I-seq: GSM736493, GSM736600, GSM736500, GSM736587, 
GSM665815, GSM665818, GSM665826, GSM701490, GSM701495, GSM701514, GSM701531, 
GSM774213, GSM774214, GSM774217, GSM774220, GSM774228, GSM774233, GSM817162, 
GSM817188; (3) TF ChIP-seq: GSM1010902, GSM1208683, GSM1208642, GSM1240820, GSM803354, 
GSM1010847, GSM1208763, GSM1010765, GSM1010790, GSM1010852, GSM1208598, GSM791411, 
GSM791412, GSM782123, GSM1122306, GSM722708, GSM1122302, GSM1122303. The detailed 
information of in-house generated and public datasets used in this study are listed in Supplementary Table 
4. All other data used in the article and its supplementary files are available from the authors on request. 
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Supplementary data 
 
Supplementary Fig. 1 Summary of PWAS screen and ChIP-seq validation. (a) A histogram shows 
number and abundance distribution of identified proteins and TFs in our screen. We could clearly observe 
a TF enrichment in our PWAS data compared to nuclear extract proteome from the LoVo cell line; (b) 
Affinity changes in respect to the TFs and other proteins. In general, the TF interactors showed higher allele 
preference than other proteins (P-values: Mann-whitney U test); (c) Overlay of the 116 PWAS experiments. 
The red density dot indicates the central cloud of the PWAS screen (P-values: Spearman correlation test); 
(d) Other candidate TF-SNP interactions (n=2 pull-downs per SNP, red and blue dots: P-values<0.01, A/B 
significance test); (e) ChIP-seq validated TF-SNP interactions, and the chromatin environment (DNase 
hypersensitivity and histone markers) and eQTL information of these SNPs. The eQTL information was 
obtained from GTEx Portal website (http://www.gtexportal.org/home/). 
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Supplementary Fig. 2 Identification of allele-specific TF binding at the rs1800734 loci. (a) Motif 
searching revealed bHLH and ETS motifs around the rs1800734 locus; (b) Significant allele-specific bHLH 
and ETS interactors of rs1800734 identified from the LoVo, SNU175, and COLO320 cell lines. Some of 
these interactors displayed cell-type specificity; (c) Examples of universal and cell-type specific interactors 
(Data are represented as mean and error bars indicate s.d., n=3 pull-downs per SNP, P-values: Student’s t-
test); (d) ELF1 ChIP-seq showed a stronger binding site at rs1800734. However, no clear allele-specific 
binding was observed, which might be caused by ETS family binding competition at rs1800734. 
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Supplementary Fig. 3 Potential gene targets of the rs1800734. (a) eQTL analysis showed a significant 
association between rs1800734 and the MLH1 expression in the healthy samples, which was lost in the 
tumor samples (P-values were calculated in FastQTL software based on Pearson correlation); (b) ChIP-
qPCR analysis confirmed TFAP4 as a specific binder for the G-allele of rs1800734 (Data are represented 
as mean and error bars indicate s.d., n=4 ChIP assays per cell line, P-values: Student’s t-test); (c) RT-
qPCR analysis confirmed no expression change of MLH1 and EPM2AIP1 between the three isogenic cell 
lines (Data are represented as mean and error bars indicate s.d., n=4 biological replicates per cell line, P-
values: Student’s t-test); (d) RNA-seq of DCLK3 qPCR products confirmed the expression of this gene in 
these isogenic cell lines. 
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Over the past decades ESCs have been subject of intense investigation. ESCs are not only one of the 
favored systems to model mammalian embryology but they also share some striking characteristics with 
tumor cells. The results presented in this thesis will therefore not only fundamentally change our view on 
G1-phase progression in the early embryo but will also provide new perspectives on how changes in 
signaling networks and TF binding contribute to cell proliferation, perturbation of differentiation and cancer 
development. 
The Cell Cycle in Two Distinct States of Pluripotency 
During close to four decades of research on in vitro-grown ESCs scientist have gained a vast amount of 
knowledge on the molecular pathways that ensure maintenance of pluripotency. Almost one decade ago 
this led to the development of a protocol that allowed scientists to propagate ESCs by solely shielding them 
from differentiation cues1. One of the impeded pathways, the FGF/ERK signaling pathway, plays a key role 
in epiblast and primitive endoderm specification in the ICM2. In ground state conditions the ERK pathway 
is abrogated and, combined with GSK3 inhibition, results in the propagation of “ground state ESCs” that 
are devoid of DNA methylation similar to epiblast cells in the early blastocyst3,4. Because of amongst others 
the higher expression of lineage specifiers it has been postulated that classically cultured serum ESCs (so 
called “naive ESCs”) reflect later stage epiblast cells5–7. Another striking difference was the elevated 
expression of CDKi’s in ground state ESCs5. These observations seemed to contradict the prevailing model 
in which the absence of CDKi’s ensured rapid progression through the G1-phase. 
In chapter 1 we set out to determine what causes these differences in expression of cell cycle regulators 
and what the consequences are. To obtain a global view on how the cell cycle differed between naive and 
ground state ESCs we first determined the distribution of ESCs throughout the cell cycle. A clear increase 
in the number of cells in G1-phase was observed upon adaptations to ground state conditions already within 
24 hours. We also observed elevated CDKi expression levels. Together these two observations lead us to 
believe that the increased expression of CDKi’s slows down G1-phase progression. Notably, these changes 
in cell cycle are fully reversible as previously reported for gene expression and DNA methylation. The 
construction of an ESC line expressing cell cycle phase-specific reporters (termed “FUCCI ESCs”) and 
allowed us to sort and investigate cell cycle phase-specific populations. Cell sorting, RNA and protein 
analysis of G1-phase cells confirmed that genes involved in S-phase entry are higher expressed in naive 
ESCs whereas several CDKi’s are upregulated in ground state ESCs. To investigate the role of the CDKi’s 
in driving the observed differences in cell cycle, we made use of genetic engineering to delete a number of 
CDKi’s, P16, P21 and P27. The combined deletion of the CDKi’s P21 and P27 was required to partially 
revert the changes in cell cycle that occurs upon adaptation to ground state conditions indicating that these 
proteins prevent CDK/Cyclin-mediated phosphorylation of RB. The fact that deletion of P21 and P27, both 
well-known inhibitors of CYCLIN E (reviewed by Foster, D. A. et al.8), enhanced G1-progression suggests 
that the elongated G1-phase in ground state ESCs is not the result of lack of CDK/cyclin activity but the 
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result of active suppression of these complexes by CDKi’s. Because CDKi’s are higher expressed in the 
ICM when compared to the epiblast (in contrast to CDKs) these findings suggest that the progression 
through G1-phase is also slower in the ICM. Because the downstream RB family proteins were supposedly 
inactive in serum ESCs we next assessed the expression of RB throughout the cell cycle9. The use of the 
FUCCI ESCs clearly showed that hypo-phosphorylated and thus active RB is present during G1-phase in 
ground state ESCs implying that G1-phase progression is actively controlled by the CDKi/CDK/Cyclin and 
RB/E2F pathways. These findings were confirmed using RB/P107/P130 Triple Knock Out (TKO) ESCs. To 
determine what abrogates the RB/E2F pathway in naive ESCs we tested both inhibitors individually and 
observed that blocking the ERK pathway reinstates the control of G1-phase progression. FGF signaling in 
the ICM is mediated via two receptors, FGFR1 and FGFR2, and dictates either epiblast or primitive 
endoderm specification2. It would be interesting to investigate which receptor is responsible for downstream 
RB phosphorylation and abrogation of G1-phase and whether this is essential for lineage specification. The 
balance between FGFR1 and FGFR2 expression might also explain the observation that the degree to 
which the number of cells in G1-phase increased upon adaptation to ground state conditions varied 
between different ESC lines. The finding that ERK-signaling drives G1-phase progression in naive serum 
but not in ground state 2i ESCs taken together with previous observations that FGF-signaling and cell 
proliferation are upregulated during later stages of embryonic development supports the model in which 
ground state 2i ESCs reflect ICM cells and naive ESCs are more similar to epiblast cells from a later 
embryonic stage6. Surprisingly, the length of the cell cycle in naive serum and ground state 2i ESCs was 
similar (12-13hrs), which could be due to the elongation of S-/G2-phase upon adaptation of ground state 
ESCs to naive serum conditions. We have also observed shortening of G1-phase upon FGF4/Activin A-
driven differentiation of ground state ESCs into EPIblast Stem Cells (EpiSC). Although doubling times 
observed in vivo (~4.4 hr) were significantly shorter than those in vitro of either ground state or naive ESCs 
we did not assess the doubling time of EpiSCs. Possibly the differentiation of ground state ESCs to EpiSCs 
is not accompanied by elongation of S-/G2-phase and results in doubling times close to 4.4 hours. It would 
be interesting to do these measurements in order to draw a comprehensive model of G1-phase progression 
and cell proliferation of ESCs in the ICM and during epiblast formation. 
The discovery of an active RB/E2F pathway in ground state ESCs made us curious whether this pathway 
could be of importance during early embryonic development. Although cells in the early embryo proliferate 
continuously under normal circumstances, stress to the mother results in diapause, a biological response 
that delays implantation of the embryo and is characterized by a severe reduction in proliferation of the ICM 
cells. Although it has to our knowledge not been determined in which phase of the cell cycle the ICM cells 
in diapaused embryos reside, in at least one out of two in vitro systems that mimic diapause ESCs reside 
in G1-phase10. Using this system, we have shown that the RB/E2F pathway regulates in vitro diapause.  
Altogether these findings provide evidence that shortened G1-phase is not an intrinsic property of 
pluripotent ESCs. Moreover, they indicate that pluripotency can co-occur with G1-phase stalling nor is 
compromised by elongation of G1-phase. These findings are in line with a previous study that shows that 
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artificial elongation of G1-phase of naive ESCs does not result in differentiation11. From these experiments 
it can however not be excluded that the absence of differentiation signals is a prerequisite for maintenance 
of pluripotency while elongating G1-phase. Whether an extremely short G1-phase can prevent 
differentiation is not entirely clear. In order to proof that a short G1-phase can prevent differentiation and 
ensures maintenance of pluripotency one would have to promote G1-phase progression while inducing 
differentiation. Such experiments have been performed12, however, considering the fact that proteins that 
positively promote cell cycle progression have a direct effect on the pluripotency network the interpretation 
of these experiments remains ambiguous13. 
 
The discovery of an RB-mediated active G1-control in ground state ESCs raises several important 
questions. RB was initially discovered as tumor suppressor gene and subsequent research has attributed 
a central role to the pocket proteins in preventing unrestricted G1-phase progression to protect genomic 
integrity14,15. Conform this model, loss of RB in ESCs results in genomic integrity16. The difference between 
naive and ground state ESCs therefore implies that, in contrast to ground state ESCs, naive ESCs are 
unable to elongate G1-phase in order to repair damaged DNA during G1-phase. Indeed, previous studies 
have shown that the DNA damage response pathway is compromised in naive ESCs and that they do not 
enter G1-arrest17. Whether ground state ESCs cope differently with DNA damage during G1-phase remains 
however to be determined. The outcome of such studies could have important implications for the clinical 
application of ESCs in organoid formation and tissue replacement. Besides their role in constricting G1-
phase progression, the pocket proteins have been shown to regulate differentiation and the expression of 
these proteins in highly pluripotent ESCs is therefore counter intuitive18. Although colony formation was not 
affected in RB/P107/P130 Triple Knock Out (TKO) ESCs and we did not find differences in the expression 
of genes the core pluripotency network, it would be interesting to study the transcriptional program of ground 
state TKO ESCs in more detail. 
 
Besides the unexpected presence of a G1-checkpoint in ESCs, the notion that ground state 2i ESCs in late 
G1-phase express hypo-phosphorylated RB is also interesting from a fundamental biological point of view. 
In the current widely accepted model passage through the R point is initiated by mitogenic stimuli that 
induce CYCLIN D-mediated mono-phosphorylation of RB and subsequent hyper-phosphorylation by 
CDK2/CYCLIN E19. Strikingly, our results suggest that hyper-phosphorylation of RB is not needed in ESCs 
for them to passage the R point and is not even a prerequisite for 2i ESCs to enter S-phase. The 
conventional western blot technique employed in our study does however not allow to discriminate between 
un-phosphorylated and hypo-phosphorylated RB and it would be interesting to determine to what extent 
RB is phosphorylated in late G1-phase ground state 2i ESCs using phospho-specific antibodies or more 
sensitive technique like 2-Dimensional IsoElectric Focussing (2D-IEF)19. In addition, the use of genetically 
engineered constitutively active RB could be used to assess whether phosphorylation is a required for 2i 
ESCs to enter S-phase. In line with previous studies our results show that inhibition of MYC results in 
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reversible G1-arrest in serum-free conditions10. Although MYC acts as a transcriptional activator of G1 
cyclins the absence of hyper-phosphorylated RB in ground state conditions suggests that MYC-mediated 
S-phase entry is independent of CDK/cyclin activity. These findings are in line with a previous report that 
indicated that MYC controls cell cycle commitment whereas the CDK/cyclin complexes tune the length of 
G1-phase20. In naive serum conditions, depletion of MYC does not result in G1-arrest of ESCs (personal 
observations and Hölzel, M. et al.21) indicating that other stimuli, presumably ERK-mediated cell cycle 
control, overcome the absence of MYC. Together our results suggest a model in which the R points is 
controlled by the MYC and the RB/E2F pathway. In addition, serum components overcome this checkpoint 
due to ERK-mediated activation of CDK/cyclin complexes. Because of its serum-free nature and the ability 
to reversibly arrest immortal karyotypically normal cells in G1-phase we believe that the 2i system could 
serve as an attractive system to study the fundamentals of G1-phase progression and the R point. 
The Role of P53 in Ground State ESCs 
Naive serum ESCs progress rapidly through the G1-phase and have lost cell cycle checkpoints that allow 
them to stall in G1-phase upon stress. P53 plays a key role in inducing G1-arrest and it had been reported 
that the P53/P21 pathway was inactive in naive ESCs. The observed increase in P21 expression in 2i ESCs 
and our observations described in chapter 1 made us hypothesize that the P53/P21 pathway is activated 
in ESCs upon adaptation to ground state 2i conditions. 
In chapter 2 we describe the experiments we did to test this hypothesis. We reasoned that P53 was a 
driving factor behind P21/P27-mediated elongation of G1-phase and therefore deleted P53 in the FUCCI 
ESCs. We indeed observed lowered expression of P21 and a shortening of G1-phase in ground state P53-
/- ESCs when compared to WT. Surprisingly, whole genome RNA-seq revealed that the expression of P21 
but not P27 is affected upon deletion of P53. However, the expression of both Rb1 and Rbl2 (coding for RB 
and P130, respectively) is significantly lower in P53KO ESCs. ChIP-seq data on P53 revealed that P53 
binds the Rb1 promoter and is therefore likely to directly control Rb1 expression. Despite the difference in 
the impact of P53 loss on naive serum and ground state 2i ESCs, the RNA-seq data clearly shows that the 
expression of target genes involved in G1-arrest is affected in both conditions. Considering the fact that 
active ERK signaling renders the pocket proteins inactive in naive serum ESCs but not in ground state 2i 
ESCs the lowered expression of Rb1 and Rbl2 could explain the discrepancy in the effect of loss of P53 
between naive and ground state ESCs. 
Whereas pathways involved in apoptosis and G1-arrest were affected in both naive and ground state ESCs 
upon loss of P53, genes involved in developmental processes were downregulated solely in ground state 
conditions. Although P53 is highly expressed in the early mouse epiblast and loss of P53 results in severe 
developmental defects the molecular mechanism behind its function is not entirely clear (reviewed by Jain, 
A. K. & Barton, M. C.22). A possible explanation for the differences between naive and ground state 
conditions are the distinct signaling pathways that are activated in both conditions. In ground state 2i ESCs, 
Chapter 5 
96 
enhanced Wnt signaling is critical and β-catenin relieves the pluripotency network from a repressive 
complex23. Interestingly, P53 has shown to govern a Wnt/β-catenin-mediated transcriptional program that 
specifies the mesoderm lineage24. These findings imply that the elevated Wnt signaling in ground state 
ESCs results in P53-mediated lineage priming. 
Two recent studies have shown that the loss of DNA methylation in ground state 2i conditions also extends 
to Imprinting Control Regions (ICRs) and results in genomic instability25,26. It is tempting to speculate that 
global DNA demethylation results in genomic instability and leads to P53 activation in ground state 2i ESCs. 
Another interesting possibility is that P53 regulates the expression of developmental genes through DNA 
methylation. A very recent study has provided evidence that P53 is crucial for DNA methylation homeostasis 
in ESCs27. Interestingly, our RNA-seq analysis revealed that the expression of DNMT1 was severely 
reduced in P53-/- ESCs in ground state conditions. Since DNMT1, but not DNMT3A and DNMT3B, is 
expressed in the pre-implantation embryo and is required for the maintenance of DNA methylation at 
imprinted loci28 these results indicate that loss of P53 in ground state ESCs might affect DNA methylation 
at those regions. Interestingly like loss of P53, reduced DNA methylation at imprinted region results in 
developmental defects29. Naive ESCs display higher DNA methylation levels due to higher expression of 
DNMT3A and DNMT3B and might therefore remain unaffected by the loss of DNMT1 4. In the early 
blastocyst the DNA methylation is actively erased and high P53 expression might therefore be crucial for 
preservation of DNA methylation at ICRs30,31. The elucidation of the role of P53 in preserving DNA 
methylation at ICRs in the early blastocyst may be an attractive line of investigation. Together, these data 
indicate that P53 is essential in early embryonic development and suggest that ground state ESCs are 
better suited to study the role of P53 during development when compared to naive ESCs. 
Pluripotency and the Cell Cycle 
Focusing on in vitro serum-grown ESCs, several studies revealed that the ESC cell cycle structure was 
characterized by a short G1-phase. Together with studies that indicated that ESCs are more sensitive to 
fate specification during G1-phase, these findings led scientists to hypothesize that the short G1-phase is 
an intrinsic property of ESCs and is ensured by the ESC-specific transcriptional program to prevent 
differentiation (reviewed in Dalton, S.32). In line with this model several studies on naive serum ESCs have 
indicated that OCT4, SOX2 and NANOG can positively affect the CDK/cyclin activity or suppress the 
RB/E2F pathway and thereby contribute to the short G1-phase. The data presented in the first two chapters 
have however fundamentally changed our perspective on the ESC-specific cell cycle. In chapter 3 we have 
reviewed whether and how members of the core pluripotency network modulate the unusual cell cycle 
structure of ESCs. When comparing naive serum to ground state 2i ESCs it is clear that the combined 
activity of ERK signaling and the lack of TCF1-driven Wnt signaling largely drives the short G1-phase of 
naive serum ESCs33,34. Since ERK signaling drives lineage specification and Wnt signaling through TCF1 
had no effect on pluripotency these findings indicate that ESCs completely shielded from differentiation 
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cues do have an intact G1-phase control pathway. Despite the elevated levels of CDKi’s and the presence 
of hypo-phosphorylated RB, ground state ESCs proliferate fast. What exactly causes rapid proliferation 
needs to be determined but the high dependence on the microRNA-processing machinery suggests that 
microRNA-mediated downregulation of the pocket proteins plays a pivotal role35. MicroRNAs play a crucial 
role during development and mature oocytes that are depleted from microRNAs fail to progress through the 
initial cell divisions36,37. Possibly, G1-phase progression in the early embryo is driven by OCT4/SOX2-
induced microRNAs expression whereas CDK/cyclin-mediated phosphorylation of RB takes over during 
later stages38,39. 
The pluripotency network does not only affect the cell cycle, but recent research has highlighted a role of 
cell cycle regulators in pluripotency and differentiation. Evidence that TFs from the pluripotency network 
are stabilized by cell cycle regulators and that upon loss of the latter ICM cells differentiate indicates that 
cell cycle regulators are essential for maintenance of pluripotency. Differentiation on the other hand 
correlates with the activity of cell cycle inhibitors and several lines of evidence indicate that the latter can 
inhibit the pluripotency network. 
ESCs and Cancer 
Both naive ESCs and tumor cells are immortal and proliferate uncontrollably. The latter have often acquired 
mutations that either result in the enhanced activity of proteins that drive G1-phase progression or prevents 
the tumor cell from entering G1 arrest40. Similarly, proteins that mediate G1-phase progression are 
constitutively activated in ESCs whereas pathways that induce G1-arrest are abolished41. In line with these 
data, the results presented in this thesis suggest that the G1-phase of tumor cells that proliferate 
uncontrollably due to constitutively activated ERK-signaling resembles that of naive ESCs (chapter 1 and 
Malumbres, M. & Barbacid, M.42). The use of the two small molecule inhibitors (2i) might therefore restore 
the RB/E2F pathway in tumor cells and restrict proliferation. Moreover, our findings suggest that P53 is not 
able to elicit its function in naive ESCs where CDK/Cyclin activity is high. Because P53 is the most 
frequently mutated gene in cancer these findings might have important implications in cancer. Our findings 
described in chapter 2 indicate that constitutive ERK signaling impacts on downstream targets of P53 
leading to the inability of ESCs to engage a proper P53-mediated G1 checkpoint. It would therefore be 
interesting to study regulators of the ERK-signaling pathway in tumor cells that do not undergo P53-
mediated cell cycle arrest. Furthermore, we have identified RB as a direct transcriptional target for P53. 
Although P53 is in general thought to prevent genomic instability via P21-mediated cell cycle arrest, our 
results suggest that P53 may prevent tumorigenesis by directly upregulating the expression RB. It would 
be worthwhile to assess whether the induced expression of RB can lower the tumorigenicity of P53-/- tumors. 
Recently developed CRISPR-based methods to induce expression of RB could possibly be employed to 
treat loss of P53-driven tumors.  
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Although these findings assume that their unrestricted proliferative nature underlies the tumorigenic 
phenotype of cancer cells, accumulating evidence over the past decades has indicated that tumorigenicity 
is often the result of flawed differentiation and  that the pluripotent ESC-like transcriptional profile is often 
found in poorly differentiated tumors43. Regarding the fact that the cell cycle machinery is able to directly 
impact on the pluripotent phenotype of cells (chapter 3) it might be feasible to target both these features 
of cancer cells. Blocking certain CDK/cyclin complexes could for instance result in simultaneous lowering 
of proliferation and degradation of pluripotency factors. The elucidation of pathway that link the cell cycle 
to pluripotency might therefore identify new therapeutic targets in cancer treatment. 
 
Cancer is often driven by mutations that lead to aberrant signaling and upregulated transcription of genes 
that promote cell cycle progression. These mutations do not only occur in coding regions but are often 
found in regulatory regions like enhancers. Similarly, Single Nucleotide Polymorphisms (SNPs) at enhancer 
sites have shown to affect TF binding and gene expression44. Genome-Wide Association Studies (GWAS) 
have identified SNPs that are associated with increased susceptibility of cancer within enhancers 
regions45,46. It is expected that these SNPs modulate TF binding and gene expression and thereby increase 
the risk for cancer. In chapter 4 we set out to study how SNPs within TF binding sites could contribute to 
ColoRectal Cancer (CRC). We have performed an unbiased Proteome-Wide Analysis of disease-
associated SNPs (PWAS) on 116 SNPs associated with CRC from publicly available GWAS databases. 
Our approach identified several TFs that showed preferential binding to the alternative allele over the 
reference allele. The replacement of the Adenine with a Guanine at rs1800734 resulted in an increased 
binding affinity of TFAP4 whereas ETS-like factors showed preferred binding to the Adenine-(A-)Allele. 
Subsequent experiments revealed that the A-allele of rs1800734 correlated with a higher expression of 
DCLK3 and that this was mediated by a long-range interaction between rs1800734 and the promoter of 
DCLK3. Interestingly, RNA-seq data from a cohort study revealed that the expression of DCLK3 correlated 
with the expression of genes involved in Epithelial-to-Mesenchymal Transition (EMT), suggesting that 
DCLK3 is an important regulator of EMT. Together these finding led us to propose a model in which the G-
allele of rs1800734 results in binding of ETS-factors that drive the expression DCLK3 through a long range 
genomic interaction and that the elevated level of DCLK3 promotes EMT and tumor initiation. 
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Summary 
At an early stage during organismal development Embryonic Stem Cells (ESCs) of the Inner Cell Mass 
(ICM) transiently reside in a pluripotent state, which means that they do not show any sign of cell fate 
specification and are able to differentiate in any desired cell type. In this thesis we have studied the cell 
cycle of pluripotent mouse ESCs and determined how extra-cellular signaling can affect G1-phase control. 
Furthermore, we have investigated how Single Nucleotide Polymorphisms (SNPs) in non-coding regions of 
the genome can affect gene expression and pre-disposition to cancer. 
Cells of the ICM proliferate fast and classically cultured serum ESCs lack G1-phase control. In chapter 1 
we have shown that ground state pluripotent ESCs deprived of ERK signaling express hypo-phosphorylated 
RB and have an elongated G1-phase when compared to pluripotent ESCs cultured in serum-rich conditions. 
The expression of the CDK-inhibitors P21 and P27 prevents phosphorylation of RB and mediates G1-phase 
elongation in ground state ESCs. On the other hand, we have shown that ERK signaling in naive serum 
ESCs results in hyper-phosphorylation of RB and fast progression through G1-phase. Although cells of the 
early developing embryo proliferate fast, proliferation is halted upon stressful conditions during a process 
termed “diapause”. The G1-checkpoint observed in 2i ESCs is actually required for an in vitro condition that 
mimics diapause. 
The reinstatement of the G1-checkpoint in ground state mouse ESCs implies that molecular pathways that 
control this checkpoint are active as well. An important cell cycle regulator that impacts on the CDK/Cyclin 
and RB/E2F pathway is P53. P53 is a well-studied tumor suppressor gene and plays a pivotal role in the 
DNA damage response pathway. P21 is an important target gene of P53 and one of the CDK-inhibitors up-
regulated in ground state ESCs when compared to naive serum ESCs. In chapter 2 we have therefor set 
out to study the role of P53 in ground state ESCs. Deletion of P53 resulted in a decreased expression of 
P21 and shortening of G1-phase in ground state ESCs. In contrast, in naive serum ESCs hardly any effect 
of the loss of P53 was detected. Together these results imply that the expression of P53 in ground state 
ESCs is necessary for the G1-checkpoint whereas the G1-checkpoint is absent in naive serum ESCs. 
Indeed, the treatment with DNA damaging agents resulted in an increase in the number of cells in G1-
phase in ground state 2i ESCs whereas a decrease in G1-phase cells was observed in naive ESCs. 
Surprisingly, transcriptome analysis revealed that the loss of P53 in both serum as well as 2i ESCs results 
in lowered expression of genes involved in cell cycle arrest and DNA damage response. It came to our 
notion that the expression of the pocket proteins RB and P130, which are inactive in serum but active in 2i 
ESCs, was severely reduced upon deletion of P53. These results were confirmed on protein level in cell 
cycle phase-sorted serum and 2i ESCs and explain the phenotype observed in 2i but not serum ESCs upon 
deletion of P53. Interestingly, in ground state ESCs the deletion of P53 was accompanied by a decreased 
expression of genes involved in developmental processes. These findings suggest a role for P53 in early 
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embryonic development and may explain the high expression of P53 in the developing embryo. Because 
such an effect was not observed in serum ESCs these results might encourage scientists to use ground 
state 2i ESCs to study the function of P53 in ESCs. 
Collectively, the results described in chapter one and two fundamentally changed the view on cell cycle 
progression and the G1-checkpoint in pluripotent ESCs. In chapter 3 of this thesis we have summarized 
existing literature on the cell cycle of pluripotent ESCs and we have discussed how our newly acquired 
insights relate to these literature. In line with the highly proliferative nature of ESCs, Transcription Factors 
(TFs) of the pluripotency network favor the expression of CDK/Cyclin complexes and microRNAs. These 
promote cell cycle progression and prevent the expression of cell cycle inhibitors, respectively. The 
observed G1-checkpoint underscores however the fact that fast cell cycle progression is not a pre-requisite 
for maintenance of pluripotency. The pluripotency network stimulates cell cycle progression, but cyclins and 
CDKs are also able to prevent degradation of SOX2, OCT4 and NANOG as well. By doing so these 
complexes prevent differentiation and contribute to the undifferentiated phenotype of ESCs. 
Cell cycle progression and differentiation are tightly linked and when either one of these biological 
processes go awry this can result in developmental defects and disease. In particular, mis-regulation of 
genes involved in cell cycle progression often result in unrestricted proliferation, a hallmark of cancer. 
Although mutations in coding regions of genes affect protein expression and often underlie the development 
of cancer, the aberrant regulation of gene expression leading to cancer development is often caused by 
mutations that do not affect coding regions but affect genomic regions that regulate genes involved in 
cancer development. In chapter 4 we have used a novel proteome-based method to assess how Single 
Nucleotide Polymorphisms within enhancer elements affect gene expression and can lead to increased 
susceptibility to cancer. We found that a base-pair mutation within the promoter region of MLH1, resulting 
in an Adenine instead of a Guanine, perturbs the binding of TFAP4 resulting in an increased expression of 
DCLK3 through a long range interaction. The analysis of RNA-sequencing data of healthy and tumor tissue 
revealed that the expression of DCLK3 correlated with Epithelial-to-Mesenchymal Transition (EMT)-related 
genes. Together, these findings suggest that the SNP affects TF binding, regulates EMT and thereby 
promotes cancer development. 
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Samenvatting 
Vroeg tijdens de embryonale ontwikkeling van een organisme bevinden de Embryonale Stam Cellen 
(ESCs) van de zogeheten Inner Cell Mass (ICM) zich tijdelijk in een pluripotente staat, wat betekent dat zij 
geen kenmerken van cel specificatie vertonen en dat zij nog in staat zijn in elk willekeurig celtype te 
differentiëren. In dit manuscript hebben wij de cel cyclus van pluripotente muis ESCs bestudeerd en 
bepaald hoe extracellulaire signalering routes de lengte van de G1-fase controleren. Bovendien hebben 
we onderzocht hoe mutaties in niet-coderende delen van het genoom genexpressie beïnvloeden en hoe 
dit predispositie tot kanker tot gevolg kan hebben. 
Cellen van de ICM prolifereren snel en ESCs gecultiveerd in serum-rijk medium (serum ESCs) missen G1-
fase controle mechanismen. In hoofdstuk 1 hebben we laten zien dat zogenaamd “ground state” 
pluripotente ESCs waarbij ERK-signalering is platgelegd (2i ESCs) een verlengde G1-fase hebben 
vergeleken met serum ESCs. De expressie van de CDK-remmers P21 en P27 verhinderd fosforylering van 
RB en medieert verlenging van G1-fase in 2i ESCs. Bovendien hebben we laten zien dat ERK signalering 
in serum ESCs resulteert in hyper-fosforylering van RB en snelle progressie door de G1-fase. Hoewel cellen 
in het vroege embryo snel delen wordt proliferatie tot een halt geroepen tijdens stressvolle omstandigheden, 
een proces dat “diapauze” wordt genoemd. Het G1-checkpoint dat we observeerden in 2i ESCs is 
noodzakelijk voor een in vitro conditie welke diapauze nabootst. 
De activatie van het G1-checkpoint in ground state ESCs impliceert dat de moleculaire signalerings 
mechanismen welke hierbij betrokken zijn geactiveerd worden. Een belangrijke cel cyclus regulator welke 
CDK/Cycline en RB/E2F signalering beïnvloedt is P53. P53 is uitgebreid bestudeerd en speelt een 
belangrijke rol tijdens herstel van DNA schade. P21 is een belangrijk eiwit dat wordt geactiveerd door P53 
en één van de CDK-remmers opgereguleerd in 2i ESCs ten opzichte van serum ESCs. In hoofdstuk 2 
hebben we de rol van P53 in 2i ESCs bestudeerd. De deletie van P53 resulteerde in verminderde expressie 
van P21 en een verkorting van de G1-fase in 2i ESCs. In serum ESCs had de deletie van P53 echter 
nauwelijks een effect. Deze resultaten impliceren dat de expressie van P53 in 2i ESCs is noodzakelijk ten 
behoeve van het G1-checkpoint, welke afwezig is in serum ESCs. De behandeling van 2i ESCs met 
chemicaliën welke DNA schade tot gevolg hebben leidde tot een toename van het aantal cellen in G1-fase. 
De behandeling van serum ESCs met dezelfde chemicaliën had echter geen toename van het aantal cellen 
in G1-fase tot gevolg. Transcriptoom analyse onthulde echter dat het verlies van P53 in zowel serum als 2i 
ESCs resulteert in de verminderde expressie van genen betrokken bij DNA schade herstel en cel cyclus 
arrest. Twee genen waarvan de expressie lager was in P53KO ESCs ten opzichte van WT ESCs waren 
Rb1 en Rbl1, coderend voor RB  en P130. Omdat deze genen inactief zijn in serum ESCs als gevolg van 
fosforylatie (hoofdstuk 1) zal de verminderde expressie in P53KO serum ESCs geen effect hebben. In 2i 
ESCs daarentegen zijn deze eiwitten niet gefosforyleerd en dus actief, wat verklaart waarom de deletie van 
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P53 in 2i ESCs een drastische effect heeft op de lengte van de G1 fase. De verlaagde expressie van RB 
werd bevestigd door verlaagde eiwit levels in zowel G1-, S- en G2-phase P53 KO cellen ten opzichte van 
WT cellen. Een andere interessante observatie was de verlaagde expressie van ontwikkelings-gerelateerde 
genen in P53 KO ESCs in 2i condities. Dit suggereerd dat P53 een rol speelt tijdens de vroege ontwikkeling, 
wat een verklaring zou zijn voor de hoge expressie van P53 in het vroege embryo. Omdat dit effect niet 
waargenomen wordt in P53 KO ESCs in serum condities zullen deze resultaten mogelijk andere 
wetenschappers ertoe aansporen om 2i ESCs te gebruiken om de rol van P53 tijdens de vroege 
ontwikkeling te bestuderen. 
De regulatie van de cell cyclus en van differentiatie zijn verbonden en wanneer er iets fout gaat in een van 
deze twee processen dank an dit leiden tot ontwikkelingsstoornissen dan wel ziektes. De mis-regulatie van 
genen betrokken bij de cel cyclus leidt vaak tot ongecontroleerde proliferatie, een kenmerk van kanker. 
Mutaties welke leiden tot verstoorde genexpressie vaak ten grondslag liggen aan het ontstaan van kanker, 
zijn deze mutaties niet altijd gelegen in genen zelf. In hoofdstuk 4 hebben we een nieuwe methode gebruikt 
om te bestuderen hoe SNPs in enhancer elementen genexpressie beinvloeden en hoe dit tot een 
verhoogde kans op kanker kan leiden. We vonden dat een base paar mutatie in de enhancer van MLH1, 
resulterend in een Adenine in plaats van een Guanine, leidt tot verlaagde binding van de transcriptie factor 
TFAP4. Bovendien was de expressive van DCLK3 verhoogd in cellijnen met de desbetreffende SNP. De 
analyse van RNA-seq data van gezond en tumor weefsel onthulde dat de expressie van DCLK4 correleert 
met die van Epithelial-to-Mesenchymal Transition (EMT)-gerelateerde genen. Tesamen suggereren deze 
bevindingen dat de SNP de binding van TFAP4 verhindert, EMT bevordert en zodoende de kans op het 
ontstaan van kanker vergroot. 
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